<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral morphine for cancer pain - Wiffen, PJ - 2016 | Cochrane Library</title> <meta content="Oral morphine for cancer pain - Wiffen, PJ - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003868.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral morphine for cancer pain - Wiffen, PJ - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003868.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003868.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Oral morphine for cancer pain" name="citation_title"/> <meta content="Philip J Wiffen" name="citation_author"/> <meta content="pwiffen@oxfordsrs.org.uk" name="citation_author_email"/> <meta content="Bee Wee" name="citation_author"/> <meta content="Churchill Hospital" name="citation_author_institution"/> <meta content="R Andrew Moore" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD003868.pub4" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/04/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003868.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003868.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003868.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Analgesics, Opioid [*administration &amp; dosage]; Morphine [*administration &amp; dosage]; Neoplasms [*complications]; Pain [*drug therapy, radiotherapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003868.pub4&amp;doi=10.1002/14651858.CD003868.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="STpJR8yz";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003868\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003868\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003868\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003868\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","th","ko","ms","ja","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003868.pub4",title:"Oral morphine for cancer pain",firstPublishedDate:"Apr 22, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003868.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003868.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003868.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003868.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003868.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003868.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003868.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003868.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003868.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003868.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>15006 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003868.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/full#CD003868-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/full#CD003868-sec-0091"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/full#CD003868-sec-0008"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/full#CD003868-sec-0013"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/full#CD003868-sec-0014"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/full#CD003868-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/full#CD003868-sec-0085"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/appendices#CD003868-sec-0103"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral morphine for cancer pain</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/information#CD003868-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Philip J Wiffen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/information#CD003868-cr-0005">Bee Wee</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003868.pub4/information#CD003868-cr-0006">R Andrew Moore</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/information/en#CD003868-sec-0115">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 April 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003868.pub4">https://doi.org/10.1002/14651858.CD003868.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003868-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003868-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003868-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003868-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003868-abs-0013">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD003868-abs-0010">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD003868-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003868-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003868-abs-0001" lang="en"> <section id="CD003868-sec-0001"> <h3 class="title" id="CD003868-sec-0001">Background</h3> <p>This is the third updated version of a Cochrane review first published in Issue 4, 2003 of <i>The Cochrane Library</i> and first updated in 2007<i>.</i> Morphine has been used for many years to relieve pain. Oral morphine in either immediate release or modified release form remains the analgesic of choice for moderate or severe cancer pain. </p> </section> <section id="CD003868-sec-0002"> <h3 class="title" id="CD003868-sec-0002">Objectives</h3> <p>To determine the efficacy of oral morphine in relieving cancer pain, and to assess the incidence and severity of adverse events. </p> </section> <section id="CD003868-sec-0003"> <h3 class="title" id="CD003868-sec-0003">Search methods</h3> <p>We searched the following databases: Cochrane Central Register of Controlled Trials (CENTRAL 2015, Issue 9); MEDLINE (1966 to October 2015); and EMBASE (1974 to October 2015). We also searched ClinicalTrials.gov (1 October 2015). </p> </section> <section id="CD003868-sec-0004"> <h3 class="title" id="CD003868-sec-0004">Selection criteria</h3> <p>Published randomised controlled trials (RCTs) using placebo or active comparators reporting on the analgesic effect of oral morphine in adults and children with cancer pain. We excluded trials with fewer than 10 participants. </p> </section> <section id="CD003868-sec-0005"> <h3 class="title" id="CD003868-sec-0005">Data collection and analysis</h3> <p>One review author extracted data, which were checked by another review author. There were insufficient comparable data for meta‐analysis to be undertaken or to produce numbers needed to treat (NNTs) for the analgesic effect. We extracted any available data on the number or proportion of participants with 'no worse than mild pain' or treatment success (very satisfied, or very good or excellent on patient global impression scales). </p> </section> <section id="CD003868-sec-0006"> <h3 class="title" id="CD003868-sec-0006">Main results</h3> <p>We identified seven new studies in this update. We excluded six, and one study is ongoing so also not included in this update. This review contains a total of 62 included studies, with 4241 participants. Thirty‐six studies used a cross‐over design ranging from one to 15 days, with the greatest number (11) for seven days for each arm of the trial. Overall we judged the included studies to be at high risk of bias because the methods of randomisation and allocation concealment were poorly reported. The primary outcomes for this review were participant‐reported pain and pain relief. </p> <p>Fifteen studies compared oral morphine modified release (Mm/r) preparations with morphine immediate release (MIR). Fourteen studies compared Mm/r in different strengths; six of these included 24‐hour modified release products. Fifteen studies compared Mm/r with other opioids. Six studies compared MIR with other opioids. Two studies compared oral Mm/r with rectal Mm/r. Three studies compared MIR with MIR by a different route of administration. Two studies compared Mm/r with Mm/r at different times and two compared MIR with MIR given at a different time. One study was found comparing each of the following: Mm/r tablet with Mm/r suspension; Mm/r with non‐opioids; MIR with non‐opioids; and oral morphine with epidural morphine. </p> <p>In the previous update, a standard of 'no worse than mild pain' was set, equivalent to a score of 30/100 mm or less on a visual analogue pain intensity scale (VAS), or the equivalent in other pain scales. Eighteen studies achieved this level of pain relief on average, and no study reported that good levels of pain relief were not attained. Where results were reported for individual participants in 17 studies, 'no worse than mild pain' was achieved by 96% of participants (362/377), and an outcome equivalent to treatment success in 63% (400/638). </p> <p>Morphine is an effective analgesic for cancer pain. Pain relief did not differ between Mm/r and MIR. Modified release versions of morphine were effective for 12‐ or 24‐hour dosing depending on the formulation. Daily doses in studies ranged from 25 mg to 2000 mg with an average of between 100 mg and 250 mg. Dose titration was undertaken with both instant release and modified release products. A small number of participants did not achieve adequate analgesia with morphine. Adverse events were common, predictable, and approximately 6% of participants discontinued treatment with morphine because of intolerable adverse events. </p> <p>The quality of the evidence is generally poor. Studies are old, often small, and were largely carried out for registration purposes and therefore were only designed to show equivalence between different formulations. </p> </section> <section id="CD003868-sec-0007"> <h3 class="title" id="CD003868-sec-0007">Authors' conclusions</h3> <p>The conclusions have not changed for this update. The effectiveness of oral morphine has stood the test of time, but the randomised trial literature for morphine is small given the importance of this medicine. Most trials recruited fewer than 100 participants and did not provide appropriate data for meta‐analysis. Only a few reported how many people had good pain relief, but where it was reported, over 90% had no worse than mild pain within a reasonably short time period. The review demonstrates the wide dose range of morphine used in studies, and that a small percentage of participants are unable to tolerate oral morphine. The review also shows the wide range of study designs, and inconsistency in cross‐over designs. Trial design was frequently based on titration of morphine or comparator to achieve adequate analgesia, then crossing participants over in cross‐over design studies. It was not clear if these trials were sufficiently powered to detect any clinical differences between formulations or comparator drugs. New studies added to the review for the previous update reinforced the view that it is possible to use modified release morphine to titrate to analgesic effect. There is qualitative evidence that oral morphine has much the same efficacy as other available opioids. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003868-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003868-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003868-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003868-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003868-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003868-abs-0015">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003868-abs-0014">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD003868-abs-0011">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003868-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003868-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD003868-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003868-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003868-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003868-abs-0002" lang="en"> <h3>Oral morphine for cancer pain</h3> <p><b>Background</b> </p> <p>Morphine taken by mouth produced good pain relief for most people with moderate or severe cancer pain. </p> <p>One person in two or three who gets cancer will suffer from pain that becomes moderate or severe in intensity. The pain tends to get worse as the cancer progresses. Morphine taken by mouth has been used since the 1950s for controlling cancer pain. In 1986 the World Health Organization recommended taking an oral solution of morphine every four hours. Morphine is now available in a number of different formats that release the morphine over various periods of time. Morphine immediate release is rapidly absorbed, and would usually be taken every four hours. Modified release tablets are available that release morphine more slowly, so that they can be taken only twice a day or even only once a day. </p> <p><b>Study characteristics</b> </p> <p>In this updated review we set out to estimate how well morphine worked, how many people had side effects, and how severe those side effects were – for example, whether they were so severe that participants stopped taking their oral morphine. </p> <p>We found 62 studies with 4241 participants. The studies were often small, compared many different preparations, and used different study designs. This made it difficult to work out whether any one tablet or preparation of oral morphine was better than any other. There did not seem to be much difference between them. </p> <p><b>Key findings</b> </p> <p>More than 9 in 10 participants had pain that went from moderate or severe before taking morphine to pain that was no worse than mild when taking morphine. More than 6 in 10 participants were very satisfied with the morphine treatment, or considered the result to be very good or excellent. Only about 1 person in 20 stopped taking morphine because of side effects. Morphine is associated with some unwanted effects, mainly constipation, and nausea and vomiting. </p> <p><b>Quality of the evidence</b> </p> <p>At one level these are good results. On another level, the quality of studies is generally poor and we could wish for more consistency in study design, and especially in study reporting, which should include the outcome of pain reduced to tolerable levels – no worse than mild pain – so that people with cancer are not bothered by pain. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003868-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003868-sec-0091"></div> <h3 class="title" id="CD003868-sec-0092">Implications for practice</h3> <section id="CD003868-sec-0092"> <p>We identified no new studies for inclusion in this update, and the conclusions remain unchanged. </p> <section id="CD003868-sec-0093"> <h5 class="title">For people with cancer pain</h5> <p>This literature review, and many years of use, shows oral morphine to be an effective analgesic in patients who suffer pain associated with cancer. Oral morphine remains the gold standard for treating moderate to severe pain. Help may be needed to manage the more common undesirable adverse effects such as constipation and nausea. </p> </section> <section id="CD003868-sec-0094"> <h5 class="title">For clinicians</h5> <p>This literature review, and many years of use, shows oral morphine to be an effective analgesic in patients who suffer pain associated with cancer. Oral morphine remains the gold standard for treating moderate to severe pain. This review demonstrates that it is possible to titrate with oral morphine of any formulation, and to be confident that most patients will achieve a high level of pain relief within at least two weeks. There is likely to be a small number of patients who do not benefit from morphine, or who may develop intolerable adverse events. </p> </section> <section id="CD003868-sec-0095"> <h5 class="title">For policy makers</h5> <p>This literature review, and many years of use, shows oral morphine to be an effective analgesic in patients who suffer pain associated with cancer. Oral morphine remains the gold standard for treating moderate to severe pain. </p> </section> <section id="CD003868-sec-0096"> <h5 class="title">For funders</h5> <p>This review demonstrates that it is possible to titrate with oral morphine of any formulation, and to be confident that most patients will achieve a high level of pain relief within at least two weeks. There is likely to be a small number of patients who do not benefit from morphine, or who may develop intolerable adverse effects and so other opioids need to be included in formularies. Oral morphine remains the gold standard for treating moderate to severe pain. </p> </section> </section> <h3 class="title" id="CD003868-sec-0097">Implications for research</h3> <section id="CD003868-sec-0097"> <section id="CD003868-sec-0098"> <h5 class="title">General</h5> <p>The quality of reporting of trials in this area continues to be disappointing. Despite this, the review shows that even with very variable descriptions of outcomes, it is possible to discern that a high proportion of patients with cancer pain can obtain good pain relief (or low pain levels) within a sensible time after beginning titration with oral morphine. </p> </section> <section id="CD003868-sec-0099"> <h5 class="title">Design</h5> <p>Two methodological issues stand out. The quality of reporting of trials continues to be poor and small studies are far too common. </p> </section> <section id="CD003868-sec-0100"> <h5 class="title">Measurement (endpoints)</h5> <p>Trials need to consider additional endpoints of no worse than mild pain as well as the impact of morphine on symptoms that raise serious concerns such as consciousness, appetite, and thirst. </p> </section> <section id="CD003868-sec-0101"> <h5 class="title">Other</h5> <p>Given that most of the studies in this review were completed within the last 20 years the obvious implication for research is to instigate a morphine trialists' collaboration in order to undertake retrospective analyses of clinical trial data, using outcomes of clear patient benefit (no worse than mild pain within two weeks of starting morphine titration). Trialist collaborations have proved highly informative, with the Antiplatelet Trialists Collaboration probably the largest example of how retrospective analysis and pooling of clinical trial data can lead to improvements in treatment. With oral morphine in cancer pain, the 62 studies with 4241 participants should provide useful information about outcomes, titration schedules, and formulations to be translated into better results for patients, and a cost‐effective approach for healthcare providers. </p> <p>A second goal would be to extend the collaboration to include other drug interventions, including other oral opioids, and formulations of opioids other than oral. </p> <p>A third goal of the collaboration would be to set guidelines for future clinical trials and systematic reviews to assess pain and pain relief by means of patient‐reported validated scales, and to present data that can be related to individual participants rather than aggregated or mean data. </p> </section> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003868-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003868-sec-0008"></div> <p>This review is the third update of a previously published review in <i>The Cochrane Library</i> (Issue 4, 2013) and first updated in 2007, evaluating the analgesic effects of oral morphine for cancer pain. </p> <p>Trials of morphine have been equivalence studies, which have attempted to show either that one form of release system is as effective as another, or compared a newer opioid with morphine. However, this literature presents a number of methodological challenges as trials may not be sufficiently powered to detect differences in efficacy or to show equivalence. Two systematic reviews of morphine pharmacokinetics have been published (<a href="./references#CD003868-bbs2-0150" title="CollinsSL , FauraCC , MooreRA , McQuayHJ . Peak plasma concentrations after oral morphine - a systematic review. Journal of Pain and Symptom Management1998;16:388-402.">Collins 1998</a>; <a href="./references#CD003868-bbs2-0152" title="FauraCC , CollinsSL , MooreRA , McQuayHJ . Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain1998;74:43-53.">Faura 1998</a>). No differences in either efficacy or adverse events between morphine modified release (Mm/r) or morphine immediate release (MIR) were discerned in a systematic review using narrow inclusion criteria (<a href="./references#CD003868-bbs2-0153" title="GoudasL , CarrDB , BlochR , BalkE , IoannidesJP , TerrinN , et al. Management of cancer pain. Evidence report/Technology Assessment No 35 ARHQ Publication No 02-E002. Rockville MD: ARHQ, 2001.">Goudas 2001</a>). The present review will bring together the randomised controlled trial (RCT) literature for oral morphine. </p> <p>The term 'modified release' replaces the term 'sustained release' used in the first version of this review. </p> <section id="CD003868-sec-0009"> <h3 class="title" id="CD003868-sec-0009">Description of the condition</h3> <p>Cancer pain is perhaps one of the most feared symptoms associated with the disease. Pain may be the first symptom that causes someone to seek medical advice that leads to a diagnosis of cancer and some 30% to 50% of all sufferers will experience moderate to severe pain (<a href="./references#CD003868-bbs2-0173" title="PortenoyRK , LesageP . Management of cancer pain. Lancet1999;353:1695-700.">Portenoy 1999b</a>). Pain can occur at any time as the disease progresses but the frequency and intensity of pain tends to increase as the cancer advances (<a href="./references#CD003868-bbs2-0173" title="PortenoyRK , LesageP . Management of cancer pain. Lancet1999;353:1695-700.">Portenoy 1999b</a>). For those with advanced cancer some 75% to 90% will experience pain that has a major impact on daily living. </p> </section> <section id="CD003868-sec-0010"> <h3 class="title" id="CD003868-sec-0010">Description of the intervention</h3> <p>Morphine in one form or another has been available for centuries, and appeared in Pliny's <i>Historia Naturalis</i> (AD 77) as opium, the resin derived from poppy sap. Morphine was extracted from opium in 1803 and named as such by Sertürner, a German pharmacist from Einbeck, in 1817 (<a href="./references#CD003868-bbs2-0176" title="ReyR . History of Pain. Paris: Editions La Decouverte, 1993. [ISBN 2-7071-2256-4]">Rey 1993</a>). Oral morphine was first recommended in England in the 1950s for the treatment of cancer pain. This was often in the form of the so‐called 'Brompton cocktail' containing cocaine and alcohol in addition to morphine or diamorphine. Treatment moved towards oral morphine alone as morphine demonstrated effective pain relief without the side effects linked to the 'cocktail'. </p> <p>Following the publication of World Health Organization (WHO) guidelines in the mid‐1980s, the oral administration of aqueous morphine solution every four hours by the clock became commonplace for moderate to severe cancer pain (<a href="./references#CD003868-bbs2-0178" title="World Health Organization. Cancer Pain Relief. Geneva: WHO, 1986.">WHO 1986</a>). Morphine in a modified release tablet was first marketed around the same time, allowing the dosage interval to be extended to 12 hours. </p> <p>Morphine, usually as the sulphate or hydrochloride salt, is available in four oral formulations: an elixir or solution of morphine in various concentrations; an immediate release tablet; a number of different preparations of modified release tablets or capsules; and modified release suspensions. Modified release tablets are available in both 12‐hour and 24‐hour release patterns and should be swallowed whole. Modified release capsules contain small coated beads and can be sprinkled over food, etc, if necessary. This review considered all RCTs for all forms of oral morphine for cancer‐related pain, defined as "pain of unspecified origin in any patient with cancer or a history of cancer". This review uses the convention as used by the British National Formulary, which uses the abbreviation m/r to describe modified release. </p> <p>The wide range of formulations and dosages (10 mg to 150 mg) allows great flexibility in the management of severe pain (<a href="./references#CD003868-bbs2-0154" title="Grahame-SmithDG , AronsonJK . Oxford Textbook of Clinical Pharmacology and Drug Therapy. 3rd edition. Oxford: Oxford University Press, 2002.">Grahame‐Smith 2002</a>). Potent opioid analgesics are particularly indicated for the relief of pain in malignant disease and often have the additional very useful actions of relieving anxiety, producing drowsiness, and allowing sleep (<a href="./references#CD003868-bbs2-0154" title="Grahame-SmithDG , AronsonJK . Oxford Textbook of Clinical Pharmacology and Drug Therapy. 3rd edition. Oxford: Oxford University Press, 2002.">Grahame‐Smith 2002</a>). However, all opioid analgesics have the potential to produce adverse events: respiratory depression, nausea and vomiting, constipation, and itching. During chronic opioid therapy, larger doses may be required to sustain the analgesic effect (tolerance) and people can be at risk of opioid withdrawal syndrome upon sudden cessation of the opioid or administration of an antagonist (physiological dependence). </p> </section> <section id="CD003868-sec-0011"> <h3 class="title" id="CD003868-sec-0011">How the intervention might work</h3> <p>Morphine is known to bind to opioid receptors to produce pain relief (<a href="./references#CD003868-bbs2-0161" title="MandalA . Morphine pharmacology. http://www.news-medical.net/health/Morphine-Pharmacology.aspx (accessed December 2015).">Mandal 2015</a>). Three different receptors have been identified. </p> <p> <ul id="CD003868-list-0001"> <li> <p>Mu receptors (subdivided into μ1, μ2, and μ3). These are found in the brainstem and the thalamus. Activation can result in pain relief, sedation, and euphoria, and can also lead to respiratory depression, constipation, and physical dependence. </p> </li> <li> <p>Kappa receptor. This is found in the limbic system, the brain stem, and spinal cord. Activation can result in pain relief, sedation, loss of breath, and dependence. </p> </li> <li> <p>Delta receptor. This is found in the brain, spinal cord, and digestive tract. Activation can result in analgesic as well as antidepressant effects. It can also lead to respiratory depression. </p> </li> </ul> </p> </section> <section id="CD003868-sec-0012"> <h3 class="title" id="CD003868-sec-0012">Why it is important to do this review</h3> <p>Morphine has long been considered the preferred choice of opioid. It is widely, though still not universally, available across the world, is comparatively cheap, and is effective orally. It is listed in the WHO essential medicines list (<a href="./references#CD003868-bbs2-0179" title="World Health Organization. WHO Essential Medicines List 17th Edition. whqlibdoc.who.int/hq/2011/a95053_eng.pdf 2011 (accessed 20 June 2013).">WHO 2011</a>). The review is important to determine the effectiveness of morphine compared to other interventions used in cancer pain. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003868-sec-0013" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003868-sec-0013"></div> <p>To determine the efficacy of oral morphine in relieving cancer pain, and to assess the incidence and severity of adverse events. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003868-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003868-sec-0014"></div> <section id="CD003868-sec-0015"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003868-sec-0016"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs), single or multiple dose, parallel or cross‐over, of any duration were eligible for inclusion in this review. We excluded studies that did not state that they were randomised. We excluded quasi‐randomised studies and trials with 10 or fewer participants (<a href="./references#CD003868-bbs2-0162" title="MooreRA , GavaghanD , TramerMR , CollinsSL , McQuayHJ . Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209-16.">Moore 1998</a>). We excluded studies that did not deal with cancer‐related pain, or did not assess pain as an outcome measure. Full journal publication was an inclusion criterion. </p> </section> <section id="CD003868-sec-0017"> <h4 class="title">Types of participants</h4> <p>Adults and children with cancer pain requiring treatment with opioids.</p> </section> <section id="CD003868-sec-0018"> <h4 class="title">Types of interventions</h4> <p>Oral morphine preparations compared with either placebo, an alternative presentation of morphine, or an active control. </p> </section> <section id="CD003868-sec-0019"> <h4 class="title">Types of outcome measures</h4> <p>Data collection included the following outcomes:</p> <p> <ul id="CD003868-list-0002"> <li> <p>participant‐reported pain (physician‐, nurse‐ or carer‐reported pain measures were not included in the analysis); </p> </li> <li> <p>pain relief expressed using validated pain scales such as pain intensity and pain relief in the form of visual analogue scales or categorical scales, or both; </p> </li> <li> <p>type of pain;</p> </li> <li> <p>rescue medication;</p> </li> <li> <p>discontinuation of treatment for any reason;</p> </li> <li> <p>adverse events, major and minor.</p> </li> </ul> </p> <p>It is becoming clear that the pain outcome desired by patients can be summarised as 'no worse than mild pain' (<a href="./references#CD003868-bbs2-0169" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400-12. [DOI: 10.1111/anae.12148]">Moore 2013a</a>), therefore we also looked for outcomes that might be equivalent to this. This was no or mild pain, ≤ 3/10 on a numerical rating scale, or ≤ 30/100 mm on a visual analogue scale. We also included patient outcome measures of satisfaction (usually very satisfied), or treatment success, or global impression of change (very good, excellent). </p> <section id="CD003868-sec-0020"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003868-list-0003"> <li> <p>Participant‐reported pain (physician‐, nurse‐ or carer‐reported pain measures were not included in the analysis). </p> </li> <li> <p>Pain relief expressed using validated pain scales such as pain intensity and pain relief in the form of visual analogue scales or categorical scales, or both. </p> </li> </ul> </p> </section> <section id="CD003868-sec-0021"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003868-list-0004"> <li> <p>Rescue medication.</p> </li> <li> <p>Discontinuation of treatment for any reason.</p> </li> <li> <p>Adverse events, major and minor.</p> </li> </ul> </p> </section> </section> </section> <section id="CD003868-sec-0022"> <h3 class="title">Search methods for identification of studies</h3> <p>We ran the search for the original review in December 2002 and ran a subsequent search for this update in October 2015. </p> <p>For the identification of studies included or considered for inclusion in this review, we developed detailed search strategies for each database searched. These were based on the search strategy developed for MEDLINE but revised appropriately for each database. Please see <a href="./appendices#CD003868-sec-0104">Appendix 1</a> for the MEDLINE search strategy, <a href="./appendices#CD003868-sec-0105">Appendix 2</a> for the EMBASE strategy, and <a href="./appendices#CD003868-sec-0106">Appendix 3</a> for the CENTRAL strategy. </p> <section id="CD003868-sec-0023"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases, without language restrictions.</p> <p> <ul id="CD003868-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL 2015, Issue 10)</p> </li> <li> <p>MEDLINE (OVID) (1966 to 7 October 2015)</p> </li> <li> <p>EMBASE (OVID) (1974 to 7 October 2015)</p> </li> </ul> </p> <p>The search attempted to identify all relevant studies irrespective of language. We assessed non‐English language papers and translated as necessary. </p> </section> <section id="CD003868-sec-0024"> <h4 class="title">Searching other resources</h4> <p>We searched <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> on 1 October 2015. </p> <section id="CD003868-sec-0025"> <h5 class="title">Handsearching</h5> <p>A database of pain trials was developed by handsearching 40 key journals (<a href="./references#CD003868-bbs2-0158" title="JadadAR , CarrollD , MooreA , McQuayH . Developing a database of published reports of randomised clinical trials in pain research. Pain1996;66:239-46.">Jadad 1996a</a>). We searched this resource for the original review, and undertook no further handsearching for this review update. </p> </section> <section id="CD003868-sec-0026"> <h5 class="title">Unpublished studies</h5> <p>We asked six pharmaceutical companies that market oral morphine products, as part of the initial review process, to provide data on published and unpublished RCTs as a check on our search strategy. We did not contact any companies for this update. </p> </section> </section> </section> <section id="CD003868-sec-0027"> <h3 class="title" id="CD003868-sec-0027">Data collection and analysis</h3> <section id="CD003868-sec-0028"> <h4 class="title">Selection of studies</h4> <p>We determined eligibility by reading the abstract of each study identified by the search. We eliminated studies that clearly did not satisfy the inclusion criteria, and we obtained full copies of the remaining studies. Two review authors made the decisions. Two review authors read these studies independently and reached agreement by discussion. We did not anonymise the studies in any way before assessment. We reported the reasons for excluding trials. </p> </section> <section id="CD003868-sec-0029"> <h4 class="title">Data extraction and management</h4> <p>Two review authors extracted data independently using a standard form and checked for agreement before entry into Review Manager 5 (<a href="./references#CD003868-bbs2-0175" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). We included information about the pain condition and number of participants treated, drug and dosing regimen, study design (placebo or active control), study duration and follow‐up, analgesic outcome measures and results, withdrawals, and adverse events (participants experiencing any adverse event or serious adverse event). </p> <p>We only extracted data from cross‐over studies from the first arm to avoid carry‐over effects and to ensure data were not double‐counted. </p> </section> <section id="CD003868-sec-0030"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For the previous update we continued to assess quality using the Oxford Quality Scale (<a href="./references#CD003868-bbs2-0159" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJ , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?Controlled Clinical Trials1996;17:1-12.">Jadad 1996b</a>), which allocates points for randomisation, blinding, and the recording of study withdrawals. The maximum possible score (indicating a trial of high methodological quality) is five. We also used the Cochrane 'Risk of bias' tool. We used the following standard parameters. </p> <p>We completed a 'Risk of bias' table for each included study, using methods adapted from those described by the Cochrane Pregnancy and Childbirth Group. Two authors independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003868-bbs2-0156" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>), with any disagreements resolved by discussion. We assessed the following for each study: </p> <p> <ul id="CD003868-list-0006"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table; computer random number generator); high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number) ‐ we excluded these studies; unclear risk of bias: the trial may or may not be free of bias. </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). We assessed the method used to conceal allocation to interventions prior to assignment to establish whether intervention allocation could have been foreseen in advance of, or during, recruitment or changed after assignment. The methods were assessed as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed, opaque, envelopes); high risk of bias (open random allocation; unsealed or non‐opaque envelopes; alternation; date of birth) ‐ these studies would be excluded; unclear risk of bias ‐ the trial may or may not be free of bias. </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We considered studies to be at low risk of bias if they stated that they were blinded and described the method used to achieve blinding (e.g. identical tablets, matched in appearance and smell); or at unknown risk if they stated that they were blinded, but did not provide an adequate description of how it was achieved. </p> </li> <li> <p>Size (checking for possible biases confounded by small size). Small studies have been shown to overestimate treatment effects, probably due to methodological weaknesses (<a href="./references#CD003868-bbs2-0168" title="MooreRA , DerryS , AldingtonD , ColeP , WiffenPJ . Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD008242. [DOI: 10.1002/14651858.CD008242.pub2]">Moore 2012</a>; <a href="./references#CD003868-bbs2-0171" title="NüeschE , TrelleS , ReichenbachS , RutjesAW , TschannenB , AltmanDG , et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ2010;341:c3515. [DOI: 10.1136/bmj.c3515.]">Nüesch 2010</a>). We considered studies to be at low risk of bias if they had 200 or more participants, at unclear risk of they had between 50 and 200 participants, and at high risk if they had fewer than 50 participants. </p> </li> <li> <p>Selective outcome reporting. We considered studies to be at low risk of bias if all outcomes were pre‐defined (for example, in a published protocol) and reported, or all clinically relevant and reasonably expected outcomes were reported; at uncertain risk of bias if it is unclear whether all pre‐defined and clinically relevant and reasonably expected outcomes were reported; and at high risk of bias if one or more clinically relevant and reasonably expected outcomes were not reported, and data on these outcomes were likely to have been recorded. </p> </li> </ul> </p> </section> <section id="CD003868-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <p>We planned to calculate NNTs as the reciprocal of the absolute risk reduction (ARR).. For unwanted effects, the NNT becomes the number needed to treat for an additional harmful outcome (NNH) and is calculated in the same manner. We would use dichotomous data to calculate risk ratio (RR) with 95% confidence intervals (CI) using a fixed‐effect model unless we found significant statistical heterogeneity (see below). We did not plan to use continuous data in analyses. In the event no data were available for these calculations. </p> </section> <section id="CD003868-sec-0032"> <h4 class="title">Unit of analysis issues</h4> <p>We planned to split the control treatment arm between active treatment arms in a single study if there was more than one active treatment arm, and they were not combined for analysis. However, this was not possible as no data were available for analysis. </p> </section> <section id="CD003868-sec-0033"> <h4 class="title">Dealing with missing data</h4> <p>We extracted data using intention‐to‐treat (ITT) analysis where the ITT population consists of participants who were randomised, took at least one dose of the assigned study medication, and provided at least one post‐baseline assessment. We assigned zero improvement to missing participants wherever possible. </p> </section> <section id="CD003868-sec-0034"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to deal with clinical heterogeneity by combining studies that examined similar conditions, and assess statistical heterogeneity visually (<a href="./references#CD003868-bbs2-0160" title="L'AbbéKA , DetskyAS , O'RourkeK . Meta-analysis in clinical research. Annals of Internal Medicine1987;107:224-33.">L'Abbé 1987</a>), and with the use of the I<sup>2</sup> statistic. If the I<sup>2</sup> value was greater than 50%, we would consider possible reasons for this. In the event there was only one included study, so heterogeneity was not an issue. </p> </section> <section id="CD003868-sec-0035"> <h4 class="title">Assessment of reporting biases</h4> <p>The aim of this review was to use dichotomous outcomes of known utility and of value to patients with pain (<a href="./references#CD003868-bbs2-0157" title="Hoffman DL,  SadoskyA ,  DukesEM ,  AlvirJ . How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?Pain2010;149(2):194-201. [DOI: 10.1016/j.pain.2009.09.017 ]">Hoffman 2010</a>; <a href="./references#CD003868-bbs2-0164" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews. Pain2010;14(7):386-9. [DOI: 10.1016/j.pain.2010.05.011]'>Moore 2010a</a>; <a href="./references#CD003868-bbs2-0165" title="MooreRA , DerryS , McQuayHJ , StraubeS , AldingtonD , WiffenP , et al. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain2010;149(2):173-6. [DOI: 10.1016/j.pain.2009.08.007]">Moore 2010b</a>; <a href="./references#CD003868-bbs2-0166" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360-4. [DOI: 10.1016/j.pain.2010.02.039]">Moore 2010c</a>; <a href="./references#CD003868-bbs2-0170" title="MooreA , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:f2690. [DOI: 10.1136/bmj.f2690]">Moore 2013b</a>). We did not extract continuous data, as these poorly reflect efficacy and utility. </p> <p>We planned to assess publication bias using a method designed to detect the amount of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean an NNT of 10 or higher; <a href="./references#CD003868-bbs2-0163" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA , editors(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978–0–931092–69–5]">Moore 2008</a>). In the event, this was not possible. </p> </section> <section id="CD003868-sec-0036"> <h4 class="title">Data synthesis</h4> <p>We planned to use a fixed‐effect model for meta‐analysis, or a random‐effects model if there was significant clinical heterogeneity and it was considered appropriate to combine studies. In this review it was not possible to generate forest plots. We planned to meta‐analyse data in Review Manager 5 (<a href="./references#CD003868-bbs2-0175" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>) and also to calculate numbers needed to treat (NNTs) and numbers needed to treat for harm (NNTHs) for adverse events (<a href="./references#CD003868-bbs2-0151" title="CookRJ , SackettDL . The number needed to treat: a clinically useful measure of treatment effect. BMJ1995;310:452-4.">Cook 1995</a>). However, there were no data that could be analysed in this way. Instead, we provided a qualitative overview of this literature. </p> <section id="CD003868-sec-0037"> <h5 class="title">Quality assessment</h5> <p>For previous versions of the review, we assessed trial quality using the Oxford Quality Scale, a five‐point assessment tool (<a href="./references#CD003868-bbs2-0159" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJ , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?Controlled Clinical Trials1996;17:1-12.">Jadad 1996b</a>). The results of the assessments are recorded in the <a href="./references#CD003868-sec-0123" title="">Characteristics of included studies</a> table, but were not used to weight studies. </p> </section> </section> <section id="CD003868-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In an earlier version, had data been available, we planned subgroup analyses for the following areas: </p> <p> <ul id="CD003868-list-0007"> <li> <p>immediate versus modified release;</p> </li> <li> <p>opiate‐naive versus previous exposure to morphine;</p> </li> <li> <p>multiple dose versus single dose;</p> </li> <li> <p>enriched enrolment versus those without enriched enrolment;</p> </li> <li> <p>studies with a quality score of three or more versus those with a quality score of one or two. </p> </li> </ul> </p> <p>However, there were no data that could be subjected to such analyses.</p> <p>We did not plan to undertake subgroup analysis as we were aware that data would not be available. </p> </section> <section id="CD003868-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We did not plan specific sensitivity analysis because the evidence base is known to be too small to allow reliable analysis. We had hoped to examine details of dose‐escalation schedules to see if this could provide some basis for a sensitivity analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003868-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003868-sec-0040"></div> <section id="CD003868-sec-0041"> <h3 class="title">Description of studies</h3> <p>This review contains 62 studies of 4241 participants. One study is included on the basis of an English language abstract but is waiting for full translation for data extraction (<a href="./references#CD003868-bbs2-0043" title="OztürkT , KaradibakK , CatalD , CakanA , TugsavulF , CirakK . Comparison of TD-fentanyl with sustained-release morphine in the pain treatment of patients with lung cancer [Akciğer Kanserli Hastaların Ağrılarının Tedavisinde Transdermal Fentanil ve Yavaş Salınımlı Morfinin Karşılaştırılması.]. Agri2008;20:20-5. ">Oztürk 2008</a>). </p> <p>In total, over 150 potentially includable studies were identified by the combined searches. All studies were of adult participants. The 62 included studies are listed, together with details of the data extracted, in the <a href="./references#CD003868-sec-0123" title="">Characteristics of included studies</a> table. Thirty‐six of the 62 studies used a cross‐over design ranging from one day each arm to 15 days. Comparisons, together with numbers of studies and participants, are listed in Summary table A. The number of cross‐over days and the number of studies is presented as Summary table B. </p> <section id="CD003868-sec-0042"> <h4 class="title">Results of the search</h4> <p>We identified seven potentially new studies in this update; we excluded six (<a href="./references#CD003868-bbs2-0077" title="CorliO , MontanariM , DeandreaS , GrecoMT , VillaniW . An exploratory analysis on the effectiveness of four strong opioids in patients with cancer pain. Pain Medicine2012;13:897-907. [DOI: 10.1111/j.1526-4637]">Corli 2012</a>; <a href="./references#CD003868-bbs2-0121" title="Prommer E (lead investigator). Methadone versus morphine for cancer-related pain. https://clinicaltrials.gov/ct2/show/NCT005739372010. ">NCT00573937 2010</a>; <a href="./references#CD003868-bbs2-0122" title="Erdek M (lead investigator). A randomized study of optimal pain management: standard pain control versus early intervention with intrathecal therapy in patients with advanced pancreatic cancer. https://clinicaltrials.gov/ct2/show/NCT006603482014. ">NCT00660348 2014</a>; <a href="./references#CD003868-bbs2-0123" title='FischM , Bearden J (lead investigators). A randomized comparison of oral methadone as a "first-switch" opioid versus opioid switching between sustained-release morphine and oxycodone for oncology-hematology outpatients with pain management problems: the "simply rotate" study. https://clinicaltrials.gov/ct2/show/NCT007268302010. '>NCT00726830 2012</a>; <a href="./references#CD003868-bbs2-0124" title="NunesB , GarciaJ , SakataR . Morphine as the first drug for treatment of cancer pain. Journal of Palliative Medicine2012;15:963-4. Sakata R (lead investigator). Morphine as the first drug for the treatment of cancer pain. https://clinicaltrials.gov/ct2/show/NCT015411242010. ">NCT01541124 2012</a>; <a href="./references#CD003868-bbs2-0134" title="ShimoyamaN , GomyoI , TeramotoO , KojimaK , HiguchiH , YukitoshiN , et al. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain. Japanese Journal of Clinical Oncology2015;45:189-96. [DOI: 10.1093/jjco/hyu182]">Shimoyama 2015</a>). See <a href="./references#CD003868-sec-0124" title="">Characteristics of excluded studies</a> for details. We placed one study in <a href="./references#CD003868-sec-0125" title="">Characteristics of ongoing studies</a> as the study is complete but no results have been published to date (<a href="./references#CD003868-bbs2-0148" title="Corli O (lead investigator). RCT comparing the analgesic efficacy of 4 therapeutic strategies based on 4 different major opioids (fentanyl, oxycodone, buprenorphine vs morphine) in cancer patients with moderate/severe pain, at the moment of starting 3rd step of WHO analgesic ladder (CERP). https://clinicaltrials.gov/ct2/show/NCT018091062014. ">NCT01809106 2014a</a>). </p> <p>Information on the flow of studies from the number of references identified in the search to the number of studies included in the review is available in <a href="#CD003868-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD003868-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003868-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_n/nCD003868-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD003868-sec-0043"> <h4 class="title">Included studies</h4> <p>The 62 studies that met the inclusion criteria contained 4241 enrolled participants. Trial size varied from 11 to 699 participants. Three studies used a single dose and the remainder were multi‐dose studies, ranging in time from three days to six weeks. The majority compared morphine modified release (Mm/r) with morphine immediate release (MIR), either as tablets or solution. Many of these were cross‐over studies over a variety of time periods, listed in Summary table B. Other comparators were noted and described, such as different opioids or morphine by different routes. The range of daily morphine doses across the studies, where reported in sufficient detail to allow calculation, was 15 mg to 2000 mg. The majority of the studies were designed to show equivalence between two morphine products. It was not generally clear if they were sufficiently powered to detect a clinically meaningful difference. </p> <p>For the first version of the review, responses were received from four pharmaceutical companies and yielded six studies (all published) not retrieved by the electronic search strategy. Attempts to contact researchers listed in <a href="http://www.controlledtrials.com" target="_blank">www.controlledtrials.com</a> proved fruitless, and we identified no unpublished studies. </p> <section id="CD003868-sec-0044"> <h5 class="title">Summary table A: Comparisons, studies, and participants</h5> <p> <div class="table" id="CD003868-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Types of studies</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of studies</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No of participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mm/r versus other opioids</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1359</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mm/r versus Mm/r different strengths or times</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1084</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mm/r versus MIR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MIR versus other opioids</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>849</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mm/r versus Mm/r rectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MIR versus MIR different times</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mm/r tablet versus Mm/r suspension</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mm/r versus non‐opioids</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MIR versus non‐opioids</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MIR versus epidural morphine</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MIR versus rectal morphine</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MIR versus intravenous morphine</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TOTALS</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>62</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4241</b> </p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD003868-sec-0045"> <h5 class="title">Summary table B: Cross‐over studies and days spent on each arm</h5> <p> <div class="table" id="CD003868-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of days per arm</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of studies</b> </p> </th> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 + 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 + 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 + 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 + 4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 + 5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 + 6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 + 7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 + 10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 + 14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 + 15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> </tbody> </table> </div> </p> </section> </section> <section id="CD003868-sec-0046"> <h4 class="title">Excluded studies</h4> <p>Excluded studies are listed together with reasons for exclusion in the <a href="./references#CD003868-sec-0124" title="">Characteristics of excluded studies</a> table. We excluded six studies for this update. </p> </section> </section> <section id="CD003868-sec-0047"> <h3 class="title">Risk of bias in included studies</h3> <p>In previous versions of this review, we assessed study quality using the Oxford Quality Scale (<a href="./references#CD003868-bbs2-0159" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJ , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?Controlled Clinical Trials1996;17:1-12.">Jadad 1996b</a>), which allocates points for randomisation, blinding, and the recording of study withdrawals. The maximum possible score (indicating a trial of high methodological quality) is five. We have retained those results in the <a href="./references#CD003868-sec-0123" title="">Characteristics of included studies</a> section but have also used the Cochrane 'Risk of bias' tool. </p> <p>Overall, the methodological quality of included trials was high with a median quality score of four. </p> <p>Thirty‐two studies explicitly mentioned pharmaceutical industry support; the majority of these had a quality score of three or more. </p> <p>For the previous update we incorporated the Cochrane 'Risk of bias' tool. The findings are listed in the 'Risk of bias' table linked to the <a href="./references#CD003868-sec-0123" title="">Characteristics of included studies</a> tables. </p> <p>The overall findings are presented in the 'Risk of bias' summary graphs (<a href="#CD003868-fig-0002">Figure 2</a> and <a href="#CD003868-fig-0003">Figure 3</a>). Of note is that only 13 studies adequately reported the method of randomisation and few reported on allocation concealment. We considered the majority of studies to be at high risk of bias due to small study size. </p> <div class="figure" id="CD003868-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003868-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_n/nCD003868-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD003868-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003868-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_n/nCD003868-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD003868-sec-0048"> <h4 class="title">Allocation</h4> <p>We judged only 10/62 studies to have an adequate description of the randomisation process used and for allocation concealment the figure dropped to 5/62. </p> </section> <section id="CD003868-sec-0049"> <h4 class="title">Blinding</h4> <p>Of the 62 included studies 22 were not double‐blind as far as we could tell.</p> </section> <section id="CD003868-sec-0050"> <h4 class="title">Incomplete outcome data</h4> <p>Reporting of data was generally good so incomplete data were not an issue and it was possible to account for all participants. </p> </section> <section id="CD003868-sec-0051"> <h4 class="title">Selective reporting</h4> <p>Reporting of data was generally good so selective reporting was not an issue.</p> </section> <section id="CD003868-sec-0052"> <h4 class="title">Other potential sources of bias</h4> <p>Only 2/62 studies included over 200 participants and 17/62 contained 50 to 199 participants.</p> <p>The quality of the evidence is generally poor. Studies are old, often small, and were largely carried out for registration purposes and therefore were only designed to show equivalence between different formulations. </p> </section> </section> <section id="CD003868-sec-0053"> <h3 class="title" id="CD003868-sec-0053">Effects of interventions</h3> <section id="CD003868-sec-0054"> <h4 class="title">1. Morphine modified release (Mm/r) compared to morphine immediate release (MIR)</h4> <p>This comparison is arguably the most important as it seeks to establish the efficacy of morphine modified release products, currently the mainstay of pain relief in cancer care. In spite of this importance the literature is small, with 15 studies consisting of 500 participants in total. None of the trials were large, having a median size of 27 participants (range 16 to 73). Eleven of the trials were of cross‐over design. The results of these trials show that Mm/r and MIR are equivalent for pain relief. No new studies were found for this comparison in this update, or the previous update (2013). </p> <section id="CD003868-sec-0055"> <h5 class="title">(a) Studies not utilising a cross‐over design</h5> <p>Four studies were parallel design. <a href="./references#CD003868-bbs2-0055" title="VentafriddaV , SaitaL , BarlettaL , SbanottoA , De ConnoF . Clinical observations on controlled release morphine in cancer pain. Journal of Pain and Symptom Management1989;4(3):124-9. ">Ventafridda 1989</a> conducted the largest of the trials. Seventy participants who were opioid‐naive received either morphine solution or Mm/r. All participants received both oral diclofenac 225 mg and oral haloperidol 20 mg daily. The study duration was 14 days. Using an integrated pain score, greater pain relief was achieved by Mm/r with fewer side effects. This occurred despite the use of a higher mean daily dose of MIR (120 mg) compared to Mm/r (90 mg). <a href="./references#CD003868-bbs2-0026" title="HoskinPJ , PoulainP , HanksGW . Controlled release morphine in cancer pain. Is a loading dose required when the formulation is changed?Anaesthesia1989;44(11):897-901. ">Hoskin 1989</a> randomised 19 participants who were stable on MIR to receive Mm/r with or without an additional dose of MIR. There was no difference in pain scores between those who received the additional dose and those receiving placebo, demonstrating that a loading dose may not be necessary when commencing Mm/r. <a href="./references#CD003868-bbs2-0031" title="KossmanB , DickW , BowdlerI , KilianJ , HechtM . Modern aspects of morphine therapy. In: Advances in Morphine Therapy. The 1983 International Symposium on Pain Control. Royal Society of Medicine International Congress and Symposium Series no 64. London: Royal Society of Medicine, 1983:73-81. ">Kossman 1983</a> compared Mm/r with a morphine cocktail (content and strength not stated) in 20 participants. The study included a pharmacokinetic component but no doses were recorded. <a href="./references#CD003868-bbs2-0029" title="KlepstadP , KaasaS , JystadA , HvalB , BorchgrevinkPC . Immediate- or sustained-release morphine for dose finding during start of morphine to cancer patients: a randomized, double-blind trial. Pain2003;101(1-2):193-8. ">Klepstad 2003</a> compared Mm/r 24‐hour release with MIR in 40 participants. Acceptable pain relief was achieved in 2.1 days (95% confidence interval (CI) 1.4 to 2.7) for MIR and 1.7 days (95% CI 1.1 to 2.3) in the Mm/r group; 10/13 in the MIR group and 13/17 in the Mm/r group were satisfied or very satisfied with pain relief. </p> </section> <section id="CD003868-sec-0056"> <h5 class="title">(b) Cross‐over studies</h5> <p>The cross‐over studies showed a wide variation in treatment periods, as with the rest of this literature. None of the studies addressed the issue of carry‐over of analgesic effect for those who received the Mm/r product. In a study by <a href="./references#CD003868-bbs2-0008" title="CundiffD , McCarthyK , SavareseJJ , KaikoR , ThomasG , GrandyR , et al. Evaluation of a cancer pain model for the testing of long-acting analgesics. The effect of MS Contin in a double-blind, randomized crossover design. Cancer1989;63(11 Suppl):2355-9. CundiffD , SavareseJ , GrandyR , MacCarthyK , KaikoR , ThomasG , et al. Evaluation of a controlled- and immediate release morphine and a unique well-controlled study design in cancer pain. Journal of Pain and Symptom Management1988;3(Suppl):18. ">Cundiff 1989</a> it was difficult to determine exactly when cross‐over occurred; however, as pain was assessed by a nurse and not by the participant the results of this trial are not considered here. </p> <p><a href="./references#CD003868-bbs2-0058" title="WalshTD , MacDonaldN , BrueraE , ShepardKV , MichaudM , ZanesR . A controlled study of sustained-release morphine sulfate tablets in chronic pain from advanced cancer. American Journal of Clinical Oncology1992;15(3):268-72. ">Walsh 1992</a> took participants who were stable on morphine or on other opioids, which were then converted to morphine. The mean daily dose at trial entry was 109 mg per day. Participants were randomised either to Mm/r or MIR using a double‐dummy technique. Cross‐over occurred at two days. There was no significant difference detected in mean daily morphine dose, visual analogue score (VAS) pain data, breakthrough pain, or use of rescue analgesia. Equally, scores for adverse events, including nausea, confusion, constipation, and anxiety, were similar. A preference for Mm/r was stated by 22 of the 33 people who entered the study. Only 27 participants were evaluated. </p> <p><a href="./references#CD003868-bbs2-0020" title="HanksGW , TwycrossRG , BlissJM . Controlled release morphine tablets: a double blind trial in patients with advanced cancer. Anaesthesia1987;42(8):840-4. ">Hanks 1987a</a> conducted a similar study although one‐third of the 27 participants dropped out early. Both intervention groups experienced adequate pain control but those on Mm/r experienced better quality sleep at night. Another study by <a href="./references#CD003868-bbs2-0057" title="WalshTD . A controlled study of MST Continus tablets for chronic pain in advanced cancer. In: WilkesE , editors(s). Advances in Morphine Therapy: International Symposium on Pain Control. London: Royal Society of Medicine, 1984:99-102. WalshTD . Clinical evaluation of slow release morphine tablets. Advances in Pain Research and Therapy1985;9:727-31. ">Walsh 1985a</a> used cross‐overs at day three and again at days five and eight. This study also reported no differences in either pain relief or side effects. The authors stated that they did not detect any carry‐over effects. No difference was detected between treatments during five‐day cross‐overs by <a href="./references#CD003868-bbs2-0015" title="FinnJW , WalshTD , MacDonaldN , BrueraE , KrebsLU , ShepardKV . Placebo-blinded study of morphine sulfate sustained-release tablets and immediate-release morphine sulfate solution in outpatients with chronic pain due to advanced cancer. Journal of Clinical Oncology1993;11(5):967-72. ">Finn 1993</a> or by <a href="./references#CD003868-bbs2-0049" title="ThirlwellMP , SloanPA , MarounJA , BoosGJ , BesnerJG , StewartJH , et al. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer1989;63(Suppl 11):2275-83. ">Thirlwell 1989</a>. A French study by <a href="./references#CD003868-bbs2-0017" title="GilletteJF , FermeC , MoisyN , MignotL , SchachR , VignauxJ , et al. Double-blind crossover clinical and pharmacokinetic comparison of oral morphine syrup and sustained release morphine sulfate capsules in patients with cancer-related pain. Clinical Drug Investigation1997;14(Suppl 1):22-7. ">Gillette 1997</a> compared Mm/r as M‐Eslon® with MIR solution in opioid‐naive participants in a double‐dummy study with a pharmacokinetic component. The participants were crossed over at six days. Pain relief was similar in both groups and the kinetic parameters were comparable. Three studies used a seven‐day cross‐over design. <a href="./references#CD003868-bbs2-0030" title="HenriksenH , KnudsenJ . Controlled evaluation and ongoing experience with sustained release morphine in patients with advanced cancer pain. In: Advances in Cancer Pain Management. The International Symposium on Pain Control. Toronto: Purdue Frederick Inc, 1986. KnudsenJ , MortensenSM , EikardB , HenriksenH . Slow-release morphine tablets compared with conventional morphine tablets in the treatment of cancer pain [Morfin-depottabletter og konventionelle morfintabletter ved cancersmerter]. Ugeskrift for Laeger1985;147(9):780-4. ">Knudsen 1985</a>, in a Danish language paper, stated that the design was "consecutively randomised" but there was no explanation of what this meant. The English abstract stated that the study was a randomised, double‐blind study and it has been included in the review on that basis. The authors reported no difference in pain relief or adverse events. Similar findings were recorded by <a href="./references#CD003868-bbs2-0013" title="DeschampsM , BandPR , HislopTG , RusthovenJ , IscoeN , WarrD . The evaluation of analgesic effects in cancer patients as exemplified by a double-blind, crossover study of immediate-release versus controlled-release morphine. Journal of Pain and Symptom Management1992;7(7):384-92. ">Deschamps 1992</a> and also by <a href="./references#CD003868-bbs2-0044" title="PanichA , CharnvejL . Comparison of morphine slow release tablet (MST) and morphine sulphate solution (MSS) in the treatment of cancer pain. Journal of Medical Association of Thailand1993;76(12):672-6. ">Panich 1993</a>. In this latter study, over 70% of the participants expressed a preference for morphine solution (MIR). As 60% of them had either neck or face cancers this may have influenced the response in favour of an easy to swallow product. </p> <p>While 29 people entered the study by <a href="./references#CD003868-bbs2-0002" title="ArkinstallWW , GoughnourBR , WhiteJA , StewartJH . Control of severe pain with sustained-release morphine tablets versus oral morphine solution. Canadian Medical Association Journal1989;140(6):653-7. GoughnourBR , ArkinstallWW , StewartJH . Analgesic response to single and multiple doses of controlled release morphine tablets and morphine oral solution in cancer patients. Cancer1989;63(Suppl 11):2294-7. ">Arkinstall 1989</a>, only 17 completed it. Again, participants were as well controlled on Mm/r twice a day as on MIR six times a day, with no reported difference in adverse events. A small number of people with non‐cancer pain were included in this sample. </p> </section> </section> <section id="CD003868-sec-0057"> <h4 class="title">2. Morphine modified release (Mm/r) comparisons ‐ different strengths, formulations, and/or dose intervals </h4> <p>Fifteen studies (1084 participants) compared Mm/r at different strengths or release profiles. Three new studies (112 participants) were added at the previous update. </p> <p>These studies can be subdivided as follows:</p> <p>(a) different dose strength combinations of 12‐hour release;</p> <p>(b) studies of 24‐hour release.</p> <section id="CD003868-sec-0058"> <h5 class="title">(a) Six studies (277 participants) examined different dose strengths or interval combinations of 12‐hour release Mm/r </h5> <p>Using a double‐blind design, <a href="./references#CD003868-bbs2-0038" title="MignaultGG , LatreilleJ , ViguieF , RicherP , LemireF , HarsanyiZ , et al. Control of cancer-related pain with MS Contin: a comparison between 12-hourly and 8-hourly administration. Journal of Pain and Symptom Management1995;10(6):416-22. ">Mignault 1995</a>, in a Canadian study, showed that 12‐hourly dosage was as effective as eight‐hourly administration. This was a small study of 19 participants; there were no differences in adverse events and the majority of participants felt that the 12‐hour regimen had advantages in terms of convenience. The assessment of high‐dose tablets of Mm/r was covered by three studies. <a href="./references#CD003868-bbs2-0045" title="PortenoyR , MaldonadoM , FitzmartinR , KaikoR , KannerR . Oral controlled release morphine sulfate. Analgesic efficacy and side effects of a 100 mg tablet in cancer pain patients. Cancer1989;63(Suppl 11):2284-8. PortenoyRK , MaldonadoM , FitzmartinR , KaikoR , KannerR . Controlled-release morphine sulfate: analgesic efficacy and side effects of a 100 mg tablet. Journal of Pain and Symptom Management1988;3(3):Suppl 16. ">Portenoy 1989</a> compared three tablets of Mm/r 30 mg (MS Contin) with one tablet of 100 mg Mm/r. Participants were stabilised on MIR over a one‐ or two‐day period then randomised to either Mm/r 100 mg or Mm/r 90 mg (3 x 30 mg) every 12 hours. Comparison of the pain intensity and rescue analgesic consumption (MIR) showed no significant differences. The reported side effect profiles were also similar. Two studies compared Mm/r 100 mg with Mm/r 200 mg (MS Contin). <a href="./references#CD003868-bbs2-0048" title="SmithKJ , MillerAJ , McKellarJ , CourtM . Morphine at gramme doses: kinetics, dynamics and clinical need. Postgraduate Medical Journal1991;67(Suppl 2):S55-9. ">Smith 1991</a> studied 20 participants who received either dose for three or four days. Doses ranged from 400 mg to 1800 mg per day. Pain assessment and pharmacokinetic monitoring confirmed similar analgesic efficacy and plasma profiles. In another three‐day cross‐over study consisting of the same formulations, <a href="./references#CD003868-bbs2-0021" title="HanksGW , HannaM , FinlayI , RadstoneDJ , KeebleT . Efficacy and pharmacokinetics of a new controlled-release morphine sulfate 200-mg tablet. Journal of Pain and Symptom Management1995;10(1):6-12. ">Hanks 1995</a> also showed comparable efficacy in a study of 25 participants. People in this study used doses of 400 mg to 2000 mg per day. A comparative study of two different Mm/r products was undertaken in 45 participants by <a href="./references#CD003868-bbs2-0025" title="HomsiJ , WalshD , LasheenW , NelsonKA , RybickiLA , BastJ , et al. A comparative study of 2 sustained-release morphine preparations for pain in advanced cancer. American Journal of Hospice and Palliative Care2010;27:99-105. ">Homsi 2010</a>. This was an open‐label study with no cross‐over, based on mean pain scores and standard error of the means (SEM); the authors claim that one product was more effective on days three to five of a five‐day study. Only the results of day three were statistically significant. The authors claim that this has clinical significance. It should be noted that the sponsors of the study produce the 'more effective' product. </p> <p>A different brand of modified release capsule was used in a Chinese study by <a href="./references#CD003868-bbs2-0062" title="XuGZ , CaiZJ , DengYP , ZhouJ , XieGR , LiuSJ . Clinical evaluation of the analgesic effect of sustained release morphine sulfate microgranules in patients with terminal cancer. Clinical Drug Investigation1997;Suppl 14(1):34-42. ">Xu 1997</a>. M‐Eslon® was compared to MS Contin® in 120 participants. Both were designed for 12‐hourly dose intervals. The study was conducted at two dose levels: 20 mg every 12 hours and 30 mg every 12 hours. No titration was permitted. Using a range of analgesic assessments there was no significant difference between the two products and adverse events were also similar. </p> </section> <section id="CD003868-sec-0059"> <h5 class="title">(b) Studies of 24‐hour release</h5> <p>Nine studies were found (807 participants) of once‐daily morphine tablet or capsule (marketed under a number of trade names including Adprem®, Kadian®, Kapanol®, Morcap® or MXL® capsules). </p> <p>MXL capsules were shown to be comparable to an equivalent dose of MS Contin in a study of 85 participants by <a href="./references#CD003868-bbs2-0042" title="O'BrienT , MortimerPG , McDonaldCJ , MillerAJ . A randomized crossover study comparing the efficacy and tolerability of a novel once-daily morphine preparation (MXL capsules) with MST Continus tablets in cancer patients with severe pain. Palliative Medicine1997;11(6):475-82. ">O'Brien 1997</a>. The comparators were MXL 60 mg versus Mm/r 30 mg twice a day. The dose could be multiplied for participants requiring higher doses. While the majority of participants needed 60 mg a day, doses up to 300 mg per day were used. There were no significant differences in pain relief between participants. The study by <a href="./references#CD003868-bbs2-0016" title="FlöterT , KochEMW , and the Kap-Cas study group. Comparison of two oral morphine formulations for chronic severe pain of malignant and non malignant origin Kapanol (R) vs MST (R). Clinical Drug Investigation1997;14(3):183-91. ">Flöter 1997</a> included people with cancer and non‐cancer pain such as post‐trauma and neuropathic pains. The authors claimed a significant difference in favour of the once‐daily product for pain intensity (VAS) when measured immediately prior to the evening dose. Data were not available for a separate analysis of the participants with cancer pain. <a href="./references#CD003868-bbs2-0005" title="BroomheadA , KerrR , TesterW , O'MearaP , MaccarroneC , BowlesR , et al. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. Journal of Pain and Symptom Management1997;14(2):63-73. ">Broomhead 1997a</a> conducted a study of 150 people with cancer pain in two separate phases. Phase one contained a placebo arm to demonstrate that the study could differentiate between active treatment and placebo. Rescue medication was available in the form of MIR. Phase two consisted of three arms: Kapanol every 24 hours, Kapanol every 12 hours, and Mm/r every 12 hours. There was no significant difference between the groups in terms of rescue medication requirement. Participants' global assessments of 'good' or 'very good' pain control was 89% for the Kapanol 24‐hour group, 76% in the Kapanol 12‐hour group, and 68% in the Mm/r group. Adverse events were similar between groups and there was no increase in adverse events associated with the larger unit dose of the once‐daily product. <a href="./references#CD003868-bbs2-0018" title="GourlayGK , CherryDA , OnleyMM , TordoffSG , ConnDA , HoodGM , et al. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain. Pain1997;69(3):295-302. ">Gourlay 1997</a> showed that there were no significant differences between Kapanol once a day and Mm/r twice a day for either analgesic effect or adverse events. The pharmacokinetic profile was much flatter for Kapanol 24‐hour, reflecting the designed release profile. </p> <p>Twenty‐nine participants were enrolled in a study comparing MS Contin XL with MS Contin (<a href="./references#CD003868-bbs2-0019" title="HagenNA , ThirlwellM , EisenhofferJ , QuiqleyP , HarsanyiZ , DarkeA . Efficacy, safety, and steady state pharmacokinetics of once-a-day controlled release morphine (MS Contin XL) in cancer pain. Journal of Pain and Symptom Management2005;29(1):80-90. ">Hagen 2005</a>). All participants experienced good pain relief though it was observed that pain scores were more stable through the day on the once daily formulation. One hundred and thirty‐four participants were titrated to relief of cancer pain with MIR then randomised to either Mm/r 24‐hour (Kadian) or Mm/r 12‐hour (MC Contin) formulations (<a href="./references#CD003868-bbs2-0028" title="KerrRO , TesterWJ . A patient preference study comparing two extended-release morphine sulfate formulations (once-daily Kadian™ versus twice-daily MS Contin™) for cancer pain. Clinical Drug Investigation2000;19(1):25-32. ">Kerr 2000</a>). Only 104 participants entered the efficacy trial, which was a cross‐over design. No dose adjustments were allowed but rescue MIR was provided; 57/104 preferred Kadian, 34/104 MS Contin, and 13/104 expressed no preference. One hundred and fifty‐three participants entered a study by <a href="./references#CD003868-bbs2-0056" title="Vielvoye-KerkmeerA , Van TinterenH , MatternC , SchüllerJ , FarnellA . Sustained release morphine in cancer pain. European Journal of Palliative Care2002;9(4):137-40. ">Vielvoye‐Kerkmeer 2002</a> but only 110 were enrolled after a 14‐day run‐in period. It was not stated why the 43 participants dropped out. No significant differences were detected between groups in terms of pain intensity, rescue analgesia, or sleep quality. A study of 38 participants compared a new once daily matrix Mm/r with twice daily Mm/r (<a href="./references#CD003868-bbs2-0046" title="RidgwayD , SopataM , BurneckisA , JespersenL , AndersenC . Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study. Journal of Pain and Symptom Management2010;39:712-20. ">Ridgway 2010</a>). The study demonstrated therapeutic equivalence and no difference for incidence of breakthrough pain or pain intensity measured for morning and evening. </p> <p>In a study about timing of the dosing of a 24‐hour Mm/r in 45 participants, <a href="./references#CD003868-bbs2-0009" title="CurrowDC , PlummerJL , CooneyNJ , GormanD , GlarePA . A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer. Journal of Pain and Symptom Management2007;34:17-23. ">Currow 2007</a> showed that there was no difference in pain control or pain during the day for either morning or evening administration. </p> </section> </section> <section id="CD003868-sec-0060"> <h4 class="title">3. Morphine modified release (Mm/r) compared to other opioids</h4> <p>Sixteen studies (1359 participants) compared morphine modified release with other opioids as either modified release or immediate release formulations. This includes four studies (418 participants) added at the previous update. </p> <p>Five comparator drugs were studied:</p> <p>(a) oxycodone (six studies: <a href="./references#CD003868-bbs2-0006" title="BrueraE , BelzileM , PituskinE , FainsingerR , DarkeA , HarsanyiZ , et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. Journal of Clinical Oncology1998;16(10):3222-9. ">Bruera 1998</a>; <a href="./references#CD003868-bbs2-0014" title="FerrellB , WisdomC , WenzlC , BrownJ . Effects of controlled released morphine on quality of life for cancer pain. Oncology Nursing Forum1989;16(4):521-6. ">Ferrell 1989</a>; <a href="./references#CD003868-bbs2-0024" title="HeiskanenT , KalsoE . Controlled-release oxycodone and morphine in cancer related pain. Pain1997;73:37-45. HeiskanenTE , RuismakiPM , SeppalaTA , KalsoEA . Morphine or oxycodone in cancer pain?Acta Oncologica2000;39(8):941-7. ">Heiskanen 2000</a>; <a href="./references#CD003868-bbs2-0032" title="LaurettiGR , OliveiraGM , PereiraNL . Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. British Journal of Cancer2003;89(11):2027-30. ">Lauretti 2003</a>; <a href="./references#CD003868-bbs2-0037" title="MercadanteS , TirelliW , DavidF , ArcaraC , FulfaroF , CasuccioA , et al. Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study. Clinical Journal of Pain2010;26(9):294-7. ">Mercadante 2010</a>; <a href="./references#CD003868-bbs2-0041" title="Mucci LoRussoP , BermanBS , SilbersteinPT , CitronML , BresslerL , WeinsteinSM , et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. European Journal of Pain1998;2:239-49. ">Mucci LoRusso 1998</a>);<br/>(b) hydromorphone (two studies: <a href="./references#CD003868-bbs2-0022" title="HannaM , ThipphawongJ . A randomized, double-blind comparison of OROS hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. ">Hanna 2008</a>; <a href="./references#CD003868-bbs2-0040" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>);<br/>(c) fentanyl transdermal (five studies: <a href="./references#CD003868-bbs2-0001" title="AhmedzaiS , BrooksD . Transdermal fentanyl versus sustained-release oral morphine in cancer. Journal of Pain and Symptom Management1997;13(5):254-61. ">Ahmedzai 1997</a>; <a href="./references#CD003868-bbs2-0036" title="MercadanteS , PorzioG , FerreraP , FulfaroF , AielliF , VernaL , et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. European Journal of Pain2008;12:1040-6. ">Mercadante 2008</a>; <a href="./references#CD003868-bbs2-0043" title="OztürkT , KaradibakK , CatalD , CakanA , TugsavulF , CirakK . Comparison of TD-fentanyl with sustained-release morphine in the pain treatment of patients with lung cancer [Akciğer Kanserli Hastaların Ağrılarının Tedavisinde Transdermal Fentanil ve Yavaş Salınımlı Morfinin Karşılaştırılması.]. Agri2008;20:20-5. ">Oztürk 2008</a>; <a href="./references#CD003868-bbs2-0053" title="Van SeventerR , SmitJM , SchipperRM , WicksMA , ZuurmondWW . Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Current Medical Research and Opinion2003;19(6):457-69. ">Van Seventer 2003</a>; <a href="./references#CD003868-bbs2-0061" title="WongJO , ChiuGL , TsaoCJ , ChangCL . Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiologica Sinica1997;35(1):25-32. ">Wong 1997</a>);<br/>(d) dextropropoxyphene (one study: <a href="./references#CD003868-bbs2-0035" title="MercadanteS , SalvaggioL , DardanoniG , AgnelloA , GarofaloS . Dextropropoxyphene versus morphine in opioid-naive cancer patients with pain. Journal of Pain and Symptom Management1998;15(2):76-81. ">Mercadante 1998</a>);<br/>(e) tramadol (one study: <a href="./references#CD003868-bbs2-0033" title="LeppartW . Analgesic efficacy and side effects of oral tramadol and morphine administered orally in the treatment of cancer pain. Nowotwory2001;51(3):257-66. ">Leppart 2001</a>);<br/>(f) methadone (one study <a href="./references#CD003868-bbs2-0007" title="BrueraE , PalmerJL , BosnjakS , RicoMA , MoyanoJ , SweeneyC , et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. Journal of Clinical Oncology2004;22(1):185-92. ">Bruera 2004</a>). </p> <section id="CD003868-sec-0061"> <h5 class="title">(a) Mm/r versus oxycodone</h5> <p>Six studies (346 participants) compared modified release oxycodone with Mm/r (<a href="./references#CD003868-bbs2-0006" title="BrueraE , BelzileM , PituskinE , FainsingerR , DarkeA , HarsanyiZ , et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. Journal of Clinical Oncology1998;16(10):3222-9. ">Bruera 1998</a>; <a href="./references#CD003868-bbs2-0014" title="FerrellB , WisdomC , WenzlC , BrownJ . Effects of controlled released morphine on quality of life for cancer pain. Oncology Nursing Forum1989;16(4):521-6. ">Ferrell 1989</a>; <a href="./references#CD003868-bbs2-0024" title="HeiskanenT , KalsoE . Controlled-release oxycodone and morphine in cancer related pain. Pain1997;73:37-45. HeiskanenTE , RuismakiPM , SeppalaTA , KalsoEA . Morphine or oxycodone in cancer pain?Acta Oncologica2000;39(8):941-7. ">Heiskanen 2000</a>; <a href="./references#CD003868-bbs2-0032" title="LaurettiGR , OliveiraGM , PereiraNL . Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. British Journal of Cancer2003;89(11):2027-30. ">Lauretti 2003</a>; <a href="./references#CD003868-bbs2-0037" title="MercadanteS , TirelliW , DavidF , ArcaraC , FulfaroF , CasuccioA , et al. Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study. Clinical Journal of Pain2010;26(9):294-7. ">Mercadante 2010</a>; <a href="./references#CD003868-bbs2-0041" title="Mucci LoRussoP , BermanBS , SilbersteinPT , CitronML , BresslerL , WeinsteinSM , et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. European Journal of Pain1998;2:239-49. ">Mucci LoRusso 1998</a>). All reported adequate analgesia with both agents when doses were titrated. One study reported the relative potency of oxycodone to morphine as 1:1.5 (<a href="./references#CD003868-bbs2-0041" title="Mucci LoRussoP , BermanBS , SilbersteinPT , CitronML , BresslerL , WeinsteinSM , et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. European Journal of Pain1998;2:239-49. ">Mucci LoRusso 1998</a>). Another reported a similar relative potency of oxycodone to morphine as 1:1.6 (<a href="./references#CD003868-bbs2-0032" title="LaurettiGR , OliveiraGM , PereiraNL . Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. British Journal of Cancer2003;89(11):2027-30. ">Lauretti 2003</a>). There do seem to be some minor differences in side effect profiles, for example, no participants experienced hallucinations on oxycodone. </p> <p>A separate Cochrane review assessing the effectiveness of oxycodone for cancer pain relief has been published (<a href="./references#CD003868-bbs2-0177" title="Schmidt-HansenM , BennettMI , ArnoldS , BromhamN , HilgartJS . Oxycodone for cancer-related pain. Cochrane Database of Systematic Reviews2015, Issue 2. Art. No: CD003870. [DOI: 10.1002/14651858.CD003870.pub5]">Schmidt‐Hansen 2015</a>). </p> <p>A study by <a href="./references#CD003868-bbs2-0014" title="FerrellB , WisdomC , WenzlC , BrownJ . Effects of controlled released morphine on quality of life for cancer pain. Oncology Nursing Forum1989;16(4):521-6. ">Ferrell 1989</a> presented a number of problems. Participants who were already receiving short‐acting analgesics (oxycodone, hydromorphone, codeine, or morphine) were randomised either to a 'no change' group or changed to Mm/r. However, no data were presented on the numbers of participants receiving each opioid. There appeared to be an assumption that the short‐acting opioids were equally effective. The authors reported that pain intensity was reduced in the Mm/r group. </p> </section> <section id="CD003868-sec-0062"> <h5 class="title">(b) Mm/r versus hydromorphone</h5> <p>Two studies (300 participants) compared hydromorphone modified release and Mm/r (<a href="./references#CD003868-bbs2-0022" title="HannaM , ThipphawongJ . A randomized, double-blind comparison of OROS hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. ">Hanna 2008</a>; <a href="./references#CD003868-bbs2-0040" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>). Two hundred participants were recruited to a multi‐national multicentre study by Hanna and colleagues. Using a double‐dummy design, participants were randomised either to twice daily Mm/r or once daily hydromorphone OROS formulation with a placebo tablet in the evening. The authors claimed a small but statistically significant benefit for hydromorphone. In another randomised cross‐over study of two three‐day treatment periods (<a href="./references#CD003868-bbs2-0040" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>), the primary outcome was the use of rescue medication. Both treatments controlled pain satisfactorily and there was no difference between the number of occasions that rescue medication was used during the last 24 hours of each treatment period. Of a subgroup that expressed a preference, only five out 38 participants preferred hydromorphone; 13 preferred morphine and the remainder had no preference. Hydromorphone is also the subject of a separate Cochrane review (<a href="./references#CD003868-bbs2-0174" title="QuigleyC . Hydromorphone for acute and chronic pain. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD003447. [DOI: 10.1002/14651858.CD003447]">Quigley 2007</a>). </p> </section> <section id="CD003868-sec-0063"> <h5 class="title">(c) Mm/r versus transdermal fentanyl</h5> <p>Transdermal (TD) fentanyl has gained in popularity over recent years; we found five studies (538 participants) comparing this agent with oral morphine (<a href="./references#CD003868-bbs2-0001" title="AhmedzaiS , BrooksD . Transdermal fentanyl versus sustained-release oral morphine in cancer. Journal of Pain and Symptom Management1997;13(5):254-61. ">Ahmedzai 1997</a>; <a href="./references#CD003868-bbs2-0036" title="MercadanteS , PorzioG , FerreraP , FulfaroF , AielliF , VernaL , et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. European Journal of Pain2008;12:1040-6. ">Mercadante 2008</a>; <a href="./references#CD003868-bbs2-0043" title="OztürkT , KaradibakK , CatalD , CakanA , TugsavulF , CirakK . Comparison of TD-fentanyl with sustained-release morphine in the pain treatment of patients with lung cancer [Akciğer Kanserli Hastaların Ağrılarının Tedavisinde Transdermal Fentanil ve Yavaş Salınımlı Morfinin Karşılaştırılması.]. Agri2008;20:20-5. ">Oztürk 2008</a>; <a href="./references#CD003868-bbs2-0053" title="Van SeventerR , SmitJM , SchipperRM , WicksMA , ZuurmondWW . Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Current Medical Research and Opinion2003;19(6):457-69. ">Van Seventer 2003</a>; <a href="./references#CD003868-bbs2-0061" title="WongJO , ChiuGL , TsaoCJ , ChangCL . Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiologica Sinica1997;35(1):25-32. ">Wong 1997</a>). <a href="./references#CD003868-bbs2-0001" title="AhmedzaiS , BrooksD . Transdermal fentanyl versus sustained-release oral morphine in cancer. Journal of Pain and Symptom Management1997;13(5):254-61. ">Ahmedzai 1997</a> compared 202 participants in a cross‐over study (not double‐blind) comparing Mm/r with transdermal fentanyl patches. They found a significant carry‐over effect so only the first phase of this trial has been analysed. Pain control was assessed by a variety of measures but no significant differences were found between Mm/r and fentanyl patches. More participants required rescue medication in the fentanyl group and the fentanyl dose more often needed to be titrated upwards. Fentanyl appeared to be less sedating than morphine both during the day and at night. Participants on fentanyl were significantly less constipated. Of 136 participants who expressed a preference, 14 had no preference, 73 preferred fentanyl, and 49 preferred morphine. In <a href="./references#CD003868-bbs2-0036" title="MercadanteS , PorzioG , FerreraP , FulfaroF , AielliF , VernaL , et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. European Journal of Pain2008;12:1040-6. ">Mercadante 2008</a>, 108 participants were randomised to receive either Mm/r or fentanyl TD or methadone in an open study. All three were found to be effective and well tolerated. A Turkish study compared Mm/r with fentanyl TD in 50 participants. Again both analgesics were found to be safe and effective but with significantly less constipation experienced in the fentanyl group (<a href="./references#CD003868-bbs2-0043" title="OztürkT , KaradibakK , CatalD , CakanA , TugsavulF , CirakK . Comparison of TD-fentanyl with sustained-release morphine in the pain treatment of patients with lung cancer [Akciğer Kanserli Hastaların Ağrılarının Tedavisinde Transdermal Fentanil ve Yavaş Salınımlı Morfinin Karşılaştırılması.]. Agri2008;20:20-5. ">Oztürk 2008</a>). In the study by <a href="./references#CD003868-bbs2-0053" title="Van SeventerR , SmitJM , SchipperRM , WicksMA , ZuurmondWW . Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Current Medical Research and Opinion2003;19(6):457-69. ">Van Seventer 2003</a>, 131 participants received either transdermal fentanyl or Mm/r. After dose titration both groups reported good pain relief. Participants reported less troublesome adverse events on fentanyl with a slightly lower incidence in the use of laxatives: 51/67 used laxatives on fentanyl and 47/64 on morphine. Both groups used MIR for breakthrough pain. A study by <a href="./references#CD003868-bbs2-0061" title="WongJO , ChiuGL , TsaoCJ , ChangCL . Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiologica Sinica1997;35(1):25-32. ">Wong 1997</a> was also randomised and open without cross‐over. Participants were converted to MIR for seven days prior to randomisation then assigned either to Mm/r or fentanyl patches. In this smaller study (20 participants per group) both groups reported good pain relief and adverse events were similar. The authors reported problems in using the manufacturer's guidance in converting the dose of morphine into an equivalent fentanyl dose. Transdermal fentanyl is the subject of a separate Cochrane review in preparation (<a href="./references#CD003868-bbs2-0155" title="HadleyG , DerryS , MooreRA , WiffenPJ . Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 10. Art. No: CD010270. [DOI: 10.1002/14651858.CD010270.pub2]">Hadley 2013</a>). </p> </section> <section id="CD003868-sec-0064"> <h5 class="title">(d) Mm/r versus dextropropoxyphene</h5> <p>Dextropropoxyphene was compared to Mm/r in 32 opioid‐naive participants by <a href="./references#CD003868-bbs2-0035" title="MercadanteS , SalvaggioL , DardanoniG , AgnelloA , GarofaloS . Dextropropoxyphene versus morphine in opioid-naive cancer patients with pain. Journal of Pain and Symptom Management1998;15(2):76-81. ">Mercadante 1998</a>. Few data were presented so clear conclusions could not be drawn. Pain relief was achieved at lower doses on dextropropoxyphene, possibly with fewer side effects, in this small study of 16 people per group. The median dose of dextropropoxyphene was 40 mg (range 10 mg to 120 mg) and for morphine it was 42 mg (range 20 mg to 600 mg). </p> </section> <section id="CD003868-sec-0065"> <h5 class="title">(e) Mm/r versus tramadol</h5> <p>A Polish study compared modified release tramadol with Mm/r in 40 opioid‐naive participants (<a href="./references#CD003868-bbs2-0033" title="LeppartW . Analgesic efficacy and side effects of oral tramadol and morphine administered orally in the treatment of cancer pain. Nowotwory2001;51(3):257-66. ">Leppart 2001</a>). Satisfactory analgesia was achieved in both groups with a mean dose for tramadol of 322 +/‐ 116 mg and for morphine 123 +/‐ 78 mg. The authors reported that morphine was more effective at treating neuropathic pain. </p> </section> <section id="CD003868-sec-0066"> <h5 class="title">(f) Mm/r versus methadone</h5> <p><a href="./references#CD003868-bbs2-0007" title="BrueraE , PalmerJL , BosnjakS , RicoMA , MoyanoJ , SweeneyC , et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. Journal of Clinical Oncology2004;22(1):185-92. ">Bruera 2004</a> compared methadone 7.5 mg every 12 hours (with an additional 5 mg every four hours for breakthrough) with Mm/r 15 mg 12‐hourly (with an additional 5 mg every four hours for breakthrough) in a study of 103 participants. At day eight 37/49 methadone and 42/54 morphine participants had greater than 20% reduction in pain intensity. There were a greater number of adverse events reported in the methadone group. </p> </section> </section> <section id="CD003868-sec-0067"> <h4 class="title">4. Morphine immediate release (MIR) compared to other opioids</h4> <p>We identified five studies (849 participants) that compared MIR with four other opioids:</p> <p>(a) Brompton Cocktail (two studies: <a href="./references#CD003868-bbs2-0034" title="MelzackR , MountBM , GordonJM . The Brompton mixture versus morphine solution given orally: effects on pain. Canadian Medical Association Journal1979;120(4):435-8. ">Melzack 1979</a>; <a href="./references#CD003868-bbs2-0051" title="TwycrossR . The measurement of pain in terminal carcinoma. Journal of International Medical Research1976;4(Suppl 2):58-67. TwycrossRG . Choice of strong analgesic in terminal cancer: diamorphine or morphine?Pain1977;3:93-104. ">Twycross 1977</a>);<br/>(b) methadone (one study: <a href="./references#CD003868-bbs2-0054" title="VentafriddaV , RipamontiC , BianchiM , SbanottoA , De ConnoF . A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. Journal of Pain and Symptom Management1986;1(4):203-7. ">Ventafridda 1986</a>);<br/>(c) tramadol (one study: <a href="./references#CD003868-bbs2-0059" title="Wilder-SmithCH , SchimkeJ , OsterwalderB , SennHJ . Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Annals of Oncology1994;5(2):141-6. ">Wilder‐Smith 1994</a>);<br/>(d) oxycodone (one study: <a href="./references#CD003868-bbs2-0027" title="KalsoE , VainioA . Morphine and oxycodone hydrochloride in the management of cancer pain. Clinical Pharmacology and Therapeutics1990;47(5):639-46. ">Kalso 1990</a>). </p> <section id="CD003868-sec-0068"> <h5 class="title">(a) MIR versus Brompton Cocktail</h5> <p>The largest study in this review enrolled 699 participants but only 146 of these crossed over after two weeks (<a href="./references#CD003868-bbs2-0051" title="TwycrossR . The measurement of pain in terminal carcinoma. Journal of International Medical Research1976;4(Suppl 2):58-67. TwycrossRG . Choice of strong analgesic in terminal cancer: diamorphine or morphine?Pain1977;3:93-104. ">Twycross 1977</a>). The study compared elixirs containing diamorphine and cocaine with a morphine and cocaine elixir. 'Brompton Cocktail' was a generic term for mixtures and elixirs containing diamorphine or morphine and cocaine with or without chlorpromazine. These are now obsolete and should not be used (<a href="./references#CD003868-bbs2-0172" title="Parfitt K (editor). Martindale. The Complete Drug Reference. 32nd edition. London: Pharmaceutical Press, 1999.">Parfitt 1999</a>). This study is of historical interest because of the large number of participants. The study did not detect any difference between the groups when the medicines were given in equi‐analgesic doses. <a href="./references#CD003868-bbs2-0034" title="MelzackR , MountBM , GordonJM . The Brompton mixture versus morphine solution given orally: effects on pain. Canadian Medical Association Journal1979;120(4):435-8. ">Melzack 1979</a> compared morphine solution and a Brompton mixture containing a variable amount of morphine, 10 mg of cocaine, and 2.5 ml of 98% ethyl alcohol, in 44 participants. Thirty completed both phases of this cross‐over study. There was no significant difference in pain scores or adverse events but it was noted that approximately 15% of participants did not obtain adequate pain relief. However, the average morphine dose was 25 mg. This study was valuable in demonstrating that cocaine did not enhance analgesia. </p> </section> <section id="CD003868-sec-0069"> <h5 class="title">(b) MIR versus methadone</h5> <p>Sixty‐six participants were entered into a study of oral morphine versus methadone, in Italy by <a href="./references#CD003868-bbs2-0054" title="VentafriddaV , RipamontiC , BianchiM , SbanottoA , De ConnoF . A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. Journal of Pain and Symptom Management1986;1(4):203-7. ">Ventafridda 1986</a>. Only those participants (N = 54) who completed the first 14 days titration were evaluated. All participants received 150 mg diclofenac and haloperidol 20 mg daily by injection. Morphine was given in a dose of 4 mg to 24 mg every four hours and methadone in a dose of 8 mg to 28 mg every six hours for the first three days then every eight hours. Pain control was demonstrated with both treatments. More participants on morphine complained of dry mouth whereas more on methadone complained of headache. The authors argue that methadone has value in cancer pain but needs to be managed differently from morphine because of accumulation of methadone during treatment. </p> </section> <section id="CD003868-sec-0070"> <h5 class="title">(c) MIR versus tramadol</h5> <p>Tramadol solution (5%) was compared to morphine solution (1%) in a cross‐over study by <a href="./references#CD003868-bbs2-0059" title="Wilder-SmithCH , SchimkeJ , OsterwalderB , SennHJ . Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Annals of Oncology1994;5(2):141-6. ">Wilder‐Smith 1994</a>. Participants reported similar pain intensities on day four. Mean daily doses were morphine 101 mg (+/‐ 58 mg) and tramadol 375 mg (+/‐ 135 mg). Eight participants preferred morphine, three favoured tramadol, and nine expressed no distinct choice. </p> </section> <section id="CD003868-sec-0071"> <h5 class="title">(d) MIR versus oxycodone</h5> <p>Oxycodone immediate release was studied against morphine immediate release in a trial of 20 participants by Kalso and Vainio (<a href="./references#CD003868-bbs2-0027" title="KalsoE , VainioA . Morphine and oxycodone hydrochloride in the management of cancer pain. Clinical Pharmacology and Therapeutics1990;47(5):639-46. ">Kalso 1990</a>). Participants were titrated by patient controlled analgesia (PCA) until free of pain then randomised to use either morphine or oxycodone. After 48 hours the intravenous dose was used to calculate the oral dose, divided into four‐hourly doses. Oxycodone was provided at a concentration of 2.7 mg/ml and morphine at 4 mg/ml to reflect relative potencies. Participants could ask for the dose to be increased if not pain‐free, or for it to be reduced if sedated at the end of each four‐hour period. Participants were crossed over after 96 hours. The mean oral morphine consumption was 168 mg in group one and 228 mg in group two. The most frequent side effect with both treatments was sedation. Oral morphine caused significantly more nausea. Hallucinations occurred only with morphine. Five participants preferred morphine, five preferred oxycodone, and 10 had no preference. </p> </section> </section> <section id="CD003868-sec-0072"> <h4 class="title">5. Morphine modified release (Mm/r) administered rectally</h4> <p>Three studies (83 participants) compared Mm/r tablets with rectal morphine modified release. In one trial this was undertaken using Mm/r tablets administered rectally (<a href="./references#CD003868-bbs2-0060" title="WilkinsonTJ , RobinsonBA , BeggEJ , DuffullSB , RavenscroftPJ , SchneiderJJ . Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients. Cancer Chemotherapy and Pharmacology1992;31(3):251-4. ">Wilkinson 1992</a>), in another controlled release suppositories were used (<a href="./references#CD003868-bbs2-0003" title="BabulN , ProvencherL , LabergeF , HarsanyiZ , MoulinD . Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain. Journal of Clinical Pharmacology1998;38(1):74-81. ">Babul 1998</a>). One study compared Mm/r with morphine suppositories (<a href="./references#CD003868-bbs2-0039" title="MizuguchiK , TakedaF , HiragaK , NakashimaM . Utility evaluation of morphine hydrocloride suppository, AN-631, in the treatment of cancer pain. Rinshou Igaku1990;6(11):2357-76. ">Mizuguchi 1990</a>). </p> <p><a href="./references#CD003868-bbs2-0060" title="WilkinsonTJ , RobinsonBA , BeggEJ , DuffullSB , RavenscroftPJ , SchneiderJJ . Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients. Cancer Chemotherapy and Pharmacology1992;31(3):251-4. ">Wilkinson 1992</a> conducted a small study of 10 participants who were stabilised on morphine and then randomised to receive Mm/r tablets either orally or rectally in a pharmacokinetic and efficacy study which was open and of cross‐over design. No significant difference was found in the 'area under the curve' (i.e. that is they had similar pharmacokinetic profiles) for parenteral morphine but fewer metabolites were measured in the rectal group. No significant difference was found between the two routes in terms of pain relief. Participants expressed a preference for the oral route. </p> <p>Twenty‐seven participants were selected for a randomised, double‐blind, double‐dummy, two‐way cross‐over study of Mm/r tablets and a commercially available Mm/r suppository (<a href="./references#CD003868-bbs2-0003" title="BabulN , ProvencherL , LabergeF , HarsanyiZ , MoulinD . Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain. Journal of Clinical Pharmacology1998;38(1):74-81. ">Babul 1998</a>). Participants stabilised on morphine were given Mm/r suppositories at the same dose as their oral requirement. Breakthrough pain was treated with approximately 10% of the daily morphine dose given orally as morphine immediate release. No other opioids or rescue medications were allowed but participants were allowed to continue on prior medication, which could include nonsteroidal anti‐inflammatory drugs (NSAIDs), antidepressants, anticonvulsants, or bisphosphonates. Twenty‐two participants completed the study. There were no significant differences between pain scores or rescue medication requirements. There was a small but significant difference between nausea scores in favour of the rectal route. No difference was detected for other adverse events. </p> <p><a href="./references#CD003868-bbs2-0039" title="MizuguchiK , TakedaF , HiragaK , NakashimaM . Utility evaluation of morphine hydrocloride suppository, AN-631, in the treatment of cancer pain. Rinshou Igaku1990;6(11):2357-76. ">Mizuguchi 1990</a> (published in Japanese) compared Mm/r as three 10 mg MS Contin tablets with three 20 mg morphine suppositories, each given twice daily for three days in a cross‐over study of 46 participants. A total of 17/46 participants reported very good pain relief on Mm/r and 14/46 using suppositories. There were no significant differences in adverse events. </p> </section> <section id="CD003868-sec-0073"> <h4 class="title">6. Morphine modified release (Mm/r) tablets compared to morphine modified release (Mm/r) oral suspension </h4> <p>A French study compared Mm/r suspension with tablets in a double‐blind, double‐dummy, cross‐over study of 52 participants (<a href="./references#CD003868-bbs2-0004" title="BoureauF , SaudubrayF , D'ArnouxC , VedrenneJ , EstèveM , RoquefeuilB , et al. A comparative study of controlled-release morphine (CRM) suspension and CRM tablets in chronic cancer pain. Journal of Pain and Symptom Management1992;7(7):393-9. ">Boureau 1992</a>). Using visual analogue scores and categorical scales, there were no significant differences between the groups regarding pain relief or other measured indicators such as activity, mood, or sleep. There was no clear participant preference for any product. Adverse events were also comparable. </p> </section> <section id="CD003868-sec-0074"> <h4 class="title">7. Morphine modified release (Mm/r) compared to non‐opioids</h4> <p>In a small study by <a href="./references#CD003868-bbs2-0012" title="DellemijnPL , VerbiestHB , Van VlietJJ , RoosPJ , VechtCJ . Medical therapy of malignant nerve pain. A randomised double-blind explanatory trial with naproxen versus slow-release morphine. European Journal of Cancer1994;30A(9):1244-50. ">Dellemijn 1994</a> 20 participants with malignant nerve pain were randomised to receive either naproxen 500 mg three times a day or Mm/r 30 mg twice a day with cross‐over at seven days for each arm. Doses were fixed, not titrated, and rescue paracetamol up to 4 g per day was allowed. Pain was assessed on a 101‐point numerical rating scale. Data from four participants were considered not evaluable so reported differences were based on only 16 participants. The authors stated that there was greater use of paracetamol as rescue medication in the morphine arms of the trial. </p> </section> <section id="CD003868-sec-0075"> <h4 class="title">8. Morphine instant release (MIR) compared to non‐opioids</h4> <p>A parallel, double‐blind study of 121 participants conducted in Spain compared two doses of dipyrone (1 g three times a day or 2 g three times a day) with oral morphine solution at a dose of 10 mg every four hours (<a href="./references#CD003868-bbs2-0047" title="RodriguezM , BarutellC , RullM , GálvezR , PállaresJ , VidalF , et al. Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain. European Journal of Cancer1994;30A(5):584-7. ">Rodriguez 1994</a>). Dipyrone is not available in many countries but is widely used in Spain and South America. Both dipyrone 2 g and morphine 10 mg showed benefits over dipyrone 1 g; more side effects were reported in the morphine group but these were not statistically significant. </p> </section> <section id="CD003868-sec-0076"> <h4 class="title">9. Oral morphine versus epidural morphine</h4> <p>A study by <a href="./references#CD003868-bbs2-0052" title="VainioA , TigerstedtI . Opioid treatment for radiating cancer pain: oral administration vs. epidural techniques. Acta Anaesthesiologica Scandinavica1988;32(3):179-85. ">Vainio 1988</a> compared oral morphine (MIR or Mm/r) with two techniques for epidural morphine administration in 30 participants with tumour involvement of the brachial or lumbar nerve plexuses. Epidural morphine was administered either via a conventional tunnelled epidural catheter or an epidural catheter connected to an implanted injection port. Participants were assigned randomly to either oral morphine (MIR or Mm/r) or to one of the two epidural groups. Doses were adjusted according to patient demand, daily during the first week and weekly thereafter. The initial dose of morphine was 46 mg to 150 mg orally or 2 mg to 12 mg epidurally. Treatment was continued for as long as possible, often until the participant died. Pain relief was similarly effective in all groups but those on epidural treatment reported significantly fewer side effects. There were some technical problems in the epidural groups with three dislocated catheters in the tunnelled group and three blocked catheters in the port group. Mean length of treatment was 108 days (+/‐ 290) in the oral group, 43 days (+/‐ 13) in the tunnelled group, and 97 days (+/‐ 23) in the port group. </p> </section> <section id="CD003868-sec-0077"> <h4 class="title">10. Morphine immediate release compared to rectal morphine</h4> <p><a href="./references#CD003868-bbs2-0011" title="De ConnoF , RipamontiC , SaitaL , MacEachernT , HansonJ , BrueraE . Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. Journal of Clinical Oncology1995;13(4):1004-8. ">De Conno 1995</a> compared morphine as a 10 mg oral solution with 10 mg of solution administered rectally as a micro enema in 34 cancer patients who had previously been treated with NSAIDs. This was a cross‐over study (two days each arm) using a double‐dummy technique. Significant pain relief was achieved faster in the rectal group, at 10 minutes compared to 60 minutes for the oral group. Pain relief remained better in the rectal group, up to 180 minutes. There was no significant difference in side effects. </p> </section> <section id="CD003868-sec-0078"> <h4 class="title">11. Morphine instant release (MIR) compared to intravenous morphine</h4> <p>A study in India of 62 participants by <a href="./references#CD003868-bbs2-0023" title="HarrisJT , Suresh KumarK , RajagopalMR . Intravenous morphine for rapid control of severe cancer pain. Palliative Medicine2003;17:248-56. ">Harris 2003</a> compared intravenous morphine with MIR. More patients achieved satisfactory pain relief at four hours with intravenous morphine but numbers were similar at 24 hours. </p> </section> <section id="CD003868-sec-0079"> <h4 class="title">12. Morphine instant release (MIR) given at different time points</h4> <p>Two studies (46 participants) examined the effects of different time points of administration of MIR in cross‐over design studies. <a href="./references#CD003868-bbs2-0010" title="DaleO , PiribauerM , KaasaS , MoksnesK , KnobelH , KlepstadP . A double-blind, randomized, crossover comparison between single-dose and double-dose immediate-release oral morphine at bedtime in cancer patients. Journal of Pain and Symptom Management2009;37:68-76. ">Dale 2009</a> compared a single evening dose followed by a second dose four hours later with a double evening dose followed by a placebo four hours later. Each dose was for one night in this two‐day study. The authors report that the two regimens were clinically equivalent. A similar study by <a href="./references#CD003868-bbs2-0050" title="ToddJ , ReesE , GwilliamB , DaviesA . An assessment of the efficacy and tolerability of a 'double dose' of normal-release morphine sulphate at bedtime. Palliative Medicine2002;16:507-12. ">Todd 2002</a> provided an evening dose followed by a second dose after four hours and another dose after eight hours. This was compared with a double evening dose followed by a regular dose after eight hours. The study was two days for each phase. The authors claim that more participants on double‐dose morphine required breakthrough analgesia than those on four‐hourly dosing. The likelihood is that neither of these studies are long enough or large enough to provide a reliable answer. </p> </section> <section id="CD003868-sec-0080"> <h4 class="title">Other aspects</h4> <section id="CD003868-sec-0081"> <h5 class="title">No worse than mild pain</h5> <p>For the previous update we examined reports to ascertain whether a pain intensity of 'no worse than mild pain' was achieved based on a visual analogue scale of pain intensity (VASPI) of 30/100 mm or less on a pain intensity VAS, or the equivalent in other pain scales. Eighteen studies reported that average pain scores on morphine were below 30/100 mm, indicating that most treated participants had no worse than mild pain (<a href="./references#CD003868-bbs2-0002" title="ArkinstallWW , GoughnourBR , WhiteJA , StewartJH . Control of severe pain with sustained-release morphine tablets versus oral morphine solution. Canadian Medical Association Journal1989;140(6):653-7. GoughnourBR , ArkinstallWW , StewartJH . Analgesic response to single and multiple doses of controlled release morphine tablets and morphine oral solution in cancer patients. Cancer1989;63(Suppl 11):2294-7. ">Arkinstall 1989</a>; <a href="./references#CD003868-bbs2-0003" title="BabulN , ProvencherL , LabergeF , HarsanyiZ , MoulinD . Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain. Journal of Clinical Pharmacology1998;38(1):74-81. ">Babul 1998</a>; <a href="./references#CD003868-bbs2-0005" title="BroomheadA , KerrR , TesterW , O'MearaP , MaccarroneC , BowlesR , et al. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. Journal of Pain and Symptom Management1997;14(2):63-73. ">Broomhead 1997a</a>; <a href="./references#CD003868-bbs2-0006" title="BrueraE , BelzileM , PituskinE , FainsingerR , DarkeA , HarsanyiZ , et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. Journal of Clinical Oncology1998;16(10):3222-9. ">Bruera 1998</a>; <a href="./references#CD003868-bbs2-0015" title="FinnJW , WalshTD , MacDonaldN , BrueraE , KrebsLU , ShepardKV . Placebo-blinded study of morphine sulfate sustained-release tablets and immediate-release morphine sulfate solution in outpatients with chronic pain due to advanced cancer. Journal of Clinical Oncology1993;11(5):967-72. ">Finn 1993</a>; <a href="./references#CD003868-bbs2-0024" title="HeiskanenT , KalsoE . Controlled-release oxycodone and morphine in cancer related pain. Pain1997;73:37-45. HeiskanenTE , RuismakiPM , SeppalaTA , KalsoEA . Morphine or oxycodone in cancer pain?Acta Oncologica2000;39(8):941-7. ">Heiskanen 2000</a>; <a href="./references#CD003868-bbs2-0025" title="HomsiJ , WalshD , LasheenW , NelsonKA , RybickiLA , BastJ , et al. A comparative study of 2 sustained-release morphine preparations for pain in advanced cancer. American Journal of Hospice and Palliative Care2010;27:99-105. ">Homsi 2010</a>; <a href="./references#CD003868-bbs2-0026" title="HoskinPJ , PoulainP , HanksGW . Controlled release morphine in cancer pain. Is a loading dose required when the formulation is changed?Anaesthesia1989;44(11):897-901. ">Hoskin 1989</a>; <a href="./references#CD003868-bbs2-0030" title="HenriksenH , KnudsenJ . Controlled evaluation and ongoing experience with sustained release morphine in patients with advanced cancer pain. In: Advances in Cancer Pain Management. The International Symposium on Pain Control. Toronto: Purdue Frederick Inc, 1986. KnudsenJ , MortensenSM , EikardB , HenriksenH . Slow-release morphine tablets compared with conventional morphine tablets in the treatment of cancer pain [Morfin-depottabletter og konventionelle morfintabletter ved cancersmerter]. Ugeskrift for Laeger1985;147(9):780-4. ">Knudsen 1985</a>; <a href="./references#CD003868-bbs2-0034" title="MelzackR , MountBM , GordonJM . The Brompton mixture versus morphine solution given orally: effects on pain. Canadian Medical Association Journal1979;120(4):435-8. ">Melzack 1979</a>; <a href="./references#CD003868-bbs2-0036" title="MercadanteS , PorzioG , FerreraP , FulfaroF , AielliF , VernaL , et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. European Journal of Pain2008;12:1040-6. ">Mercadante 2008</a>; <a href="./references#CD003868-bbs2-0037" title="MercadanteS , TirelliW , DavidF , ArcaraC , FulfaroF , CasuccioA , et al. Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study. Clinical Journal of Pain2010;26(9):294-7. ">Mercadante 2010</a>; <a href="./references#CD003868-bbs2-0041" title="Mucci LoRussoP , BermanBS , SilbersteinPT , CitronML , BresslerL , WeinsteinSM , et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. European Journal of Pain1998;2:239-49. ">Mucci LoRusso 1998</a>; <a href="./references#CD003868-bbs2-0046" title="RidgwayD , SopataM , BurneckisA , JespersenL , AndersenC . Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study. Journal of Pain and Symptom Management2010;39:712-20. ">Ridgway 2010</a>; <a href="./references#CD003868-bbs2-0054" title="VentafriddaV , RipamontiC , BianchiM , SbanottoA , De ConnoF . A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. Journal of Pain and Symptom Management1986;1(4):203-7. ">Ventafridda 1986</a>; <a href="./references#CD003868-bbs2-0055" title="VentafriddaV , SaitaL , BarlettaL , SbanottoA , De ConnoF . Clinical observations on controlled release morphine in cancer pain. Journal of Pain and Symptom Management1989;4(3):124-9. ">Ventafridda 1989</a>; <a href="./references#CD003868-bbs2-0056" title="Vielvoye-KerkmeerA , Van TinterenH , MatternC , SchüllerJ , FarnellA . Sustained release morphine in cancer pain. European Journal of Palliative Care2002;9(4):137-40. ">Vielvoye‐Kerkmeer 2002</a>; <a href="./references#CD003868-bbs2-0058" title="WalshTD , MacDonaldN , BrueraE , ShepardKV , MichaudM , ZanesR . A controlled study of sustained-release morphine sulfate tablets in chronic pain from advanced cancer. American Journal of Clinical Oncology1992;15(3):268-72. ">Walsh 1992</a>). No study reported that average pain on treatment with oral morphine was above 30/100 mm or equivalent. </p> <p>Eighteen studies recorded the proportion of participants achieving either no worse than mild pain (<a href="./references#CD003868-bbs2-0010" title="DaleO , PiribauerM , KaasaS , MoksnesK , KnobelH , KlepstadP . A double-blind, randomized, crossover comparison between single-dose and double-dose immediate-release oral morphine at bedtime in cancer patients. Journal of Pain and Symptom Management2009;37:68-76. ">Dale 2009</a>; <a href="./references#CD003868-bbs2-0012" title="DellemijnPL , VerbiestHB , Van VlietJJ , RoosPJ , VechtCJ . Medical therapy of malignant nerve pain. A randomised double-blind explanatory trial with naproxen versus slow-release morphine. European Journal of Cancer1994;30A(9):1244-50. ">Dellemijn 1994</a>; <a href="./references#CD003868-bbs2-0013" title="DeschampsM , BandPR , HislopTG , RusthovenJ , IscoeN , WarrD . The evaluation of analgesic effects in cancer patients as exemplified by a double-blind, crossover study of immediate-release versus controlled-release morphine. Journal of Pain and Symptom Management1992;7(7):384-92. ">Deschamps 1992</a>; <a href="./references#CD003868-bbs2-0017" title="GilletteJF , FermeC , MoisyN , MignotL , SchachR , VignauxJ , et al. Double-blind crossover clinical and pharmacokinetic comparison of oral morphine syrup and sustained release morphine sulfate capsules in patients with cancer-related pain. Clinical Drug Investigation1997;14(Suppl 1):22-7. ">Gillette 1997</a>; <a href="./references#CD003868-bbs2-0018" title="GourlayGK , CherryDA , OnleyMM , TordoffSG , ConnDA , HoodGM , et al. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain. Pain1997;69(3):295-302. ">Gourlay 1997</a>; <a href="./references#CD003868-bbs2-0020" title="HanksGW , TwycrossRG , BlissJM . Controlled release morphine tablets: a double blind trial in patients with advanced cancer. Anaesthesia1987;42(8):840-4. ">Hanks 1987a</a>; <a href="./references#CD003868-bbs2-0031" title="KossmanB , DickW , BowdlerI , KilianJ , HechtM . Modern aspects of morphine therapy. In: Advances in Morphine Therapy. The 1983 International Symposium on Pain Control. Royal Society of Medicine International Congress and Symposium Series no 64. London: Royal Society of Medicine, 1983:73-81. ">Kossman 1983</a>; <a href="./references#CD003868-bbs2-0040" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>; <a href="./references#CD003868-bbs2-0042" title="O'BrienT , MortimerPG , McDonaldCJ , MillerAJ . A randomized crossover study comparing the efficacy and tolerability of a novel once-daily morphine preparation (MXL capsules) with MST Continus tablets in cancer patients with severe pain. Palliative Medicine1997;11(6):475-82. ">O'Brien 1997</a>), or some global outcome indicating satisfaction or success (<a href="./references#CD003868-bbs2-0001" title="AhmedzaiS , BrooksD . Transdermal fentanyl versus sustained-release oral morphine in cancer. Journal of Pain and Symptom Management1997;13(5):254-61. ">Ahmedzai 1997</a>; <a href="./references#CD003868-bbs2-0005" title="BroomheadA , KerrR , TesterW , O'MearaP , MaccarroneC , BowlesR , et al. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. Journal of Pain and Symptom Management1997;14(2):63-73. ">Broomhead 1997a</a>; <a href="./references#CD003868-bbs2-0007" title="BrueraE , PalmerJL , BosnjakS , RicoMA , MoyanoJ , SweeneyC , et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. Journal of Clinical Oncology2004;22(1):185-92. ">Bruera 2004</a>; <a href="./references#CD003868-bbs2-0009" title="CurrowDC , PlummerJL , CooneyNJ , GormanD , GlarePA . A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer. Journal of Pain and Symptom Management2007;34:17-23. ">Currow 2007</a>; <a href="./references#CD003868-bbs2-0062" title="XuGZ , CaiZJ , DengYP , ZhouJ , XieGR , LiuSJ . Clinical evaluation of the analgesic effect of sustained release morphine sulfate microgranules in patients with terminal cancer. Clinical Drug Investigation1997;Suppl 14(1):34-42. ">Xu 1997</a>; <a href="./references#CD003868-bbs2-0022" title="HannaM , ThipphawongJ . A randomized, double-blind comparison of OROS hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. ">Hanna 2008</a>; <a href="./references#CD003868-bbs2-0029" title="KlepstadP , KaasaS , JystadA , HvalB , BorchgrevinkPC . Immediate- or sustained-release morphine for dose finding during start of morphine to cancer patients: a randomized, double-blind trial. Pain2003;101(1-2):193-8. ">Klepstad 2003</a>; <a href="./references#CD003868-bbs2-0038" title="MignaultGG , LatreilleJ , ViguieF , RicherP , LemireF , HarsanyiZ , et al. Control of cancer-related pain with MS Contin: a comparison between 12-hourly and 8-hourly administration. Journal of Pain and Symptom Management1995;10(6):416-22. ">Mignault 1995</a>; <a href="./references#CD003868-bbs2-0047" title="RodriguezM , BarutellC , RullM , GálvezR , PállaresJ , VidalF , et al. Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain. European Journal of Cancer1994;30A(5):584-7. ">Rodriguez 1994</a>). </p> <p>The outcome of 'no worse than mild pain' was achieved by 96% of participants (362/377), with consistently high levels of response (<a href="#CD003868-fig-0004">Figure 4</a>). For an outcome equivalent to treatment success, successful pain control, or participant global evaluation of very good or excellent, results were more variable, with an overall success rate of 63% (400/638; <a href="#CD003868-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD003868-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Percentage of participants with oral morphine reporting no worse than mild pain. The size of the symbol is proportional to the size of the sample" data-id="CD003868-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_n/nCD003868-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Percentage of participants with oral morphine reporting no worse than mild pain. The size of the symbol is proportional to the size of the sample </p> </div> </div> </div> <div class="figure" id="CD003868-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Percentage of participants with oral morphine reporting an outcome equivalent to treatment success. The size of the symbol is proportional to the size of the sample" data-id="CD003868-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_n/nCD003868-FIG-05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Percentage of participants with oral morphine reporting an outcome equivalent to treatment success. The size of the symbol is proportional to the size of the sample </p> </div> </div> </div> </section> <section id="CD003868-sec-0082"> <h5 class="title">Effectiveness of morphine and dose</h5> <p>The effectiveness of morphine is demonstrated by the literature with titration to effect being common. The more important question concerns dose. The range of doses used in the reported studies was wide, varying from 25 mg/day (<a href="./references#CD003868-bbs2-0034" title="MelzackR , MountBM , GordonJM . The Brompton mixture versus morphine solution given orally: effects on pain. Canadian Medical Association Journal1979;120(4):435-8. ">Melzack 1979</a>), to 300 mg/day (<a href="./references#CD003868-bbs2-0017" title="GilletteJF , FermeC , MoisyN , MignotL , SchachR , VignauxJ , et al. Double-blind crossover clinical and pharmacokinetic comparison of oral morphine syrup and sustained release morphine sulfate capsules in patients with cancer-related pain. Clinical Drug Investigation1997;14(Suppl 1):22-7. ">Gillette 1997</a>) for opioid‐naive participants. The maximum dose recorded was 2000 mg/day (<a href="./references#CD003868-bbs2-0021" title="HanksGW , HannaM , FinlayI , RadstoneDJ , KeebleT . Efficacy and pharmacokinetics of a new controlled-release morphine sulfate 200-mg tablet. Journal of Pain and Symptom Management1995;10(1):6-12. ">Hanks 1995</a>). Mean daily doses presented by a number of investigators were from 100 mg/day to 250 mg/day. </p> </section> <section id="CD003868-sec-0083"> <h5 class="title">Study withdrawals</h5> <p>Withdrawals were common in these studies due to the frail nature of the participants. In spite of this, not every study reported the number of participants and reasons for withdrawals and dropouts. In the study by <a href="./references#CD003868-bbs2-0051" title="TwycrossR . The measurement of pain in terminal carcinoma. Journal of International Medical Research1976;4(Suppl 2):58-67. TwycrossRG . Choice of strong analgesic in terminal cancer: diamorphine or morphine?Pain1977;3:93-104. ">Twycross 1977</a>, 699 participants were enrolled but only 146 were able to cross over to the second phase of the study after two weeks. </p> <p>In many cases withdrawal was due to disease progression. Rates for withdrawal due to adverse events are reported below. </p> <p>Nine studies reported withdrawals due to a lack of analgesic efficacy; all studies titrated participants to satisfactory pain relief and provided rescue medication. A total of 41 out of 544 participants (7%) withdrew. In one study this was linked to unstable pain control after the titration phase (<a href="./references#CD003868-bbs2-0027" title="KalsoE , VainioA . Morphine and oxycodone hydrochloride in the management of cancer pain. Clinical Pharmacology and Therapeutics1990;47(5):639-46. ">Kalso 1990</a>). Other reasons for withdrawal included death during the study and protocol violations. </p> </section> <section id="CD003868-sec-0084"> <h5 class="title">Withdrawal due to adverse events</h5> <p>Twenty‐six studies reported on participants withdrawing due to adverse events. In two studies, it was not possible to determine how many withdrew while on fentanyl and how many withdrew on morphine (<a href="./references#CD003868-bbs2-0001" title="AhmedzaiS , BrooksD . Transdermal fentanyl versus sustained-release oral morphine in cancer. Journal of Pain and Symptom Management1997;13(5):254-61. ">Ahmedzai 1997</a>; <a href="./references#CD003868-bbs2-0061" title="WongJO , ChiuGL , TsaoCJ , ChangCL . Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiologica Sinica1997;35(1):25-32. ">Wong 1997</a>). In the remaining 24 studies, 154 participants out of a total of 2162 participants dropped out. This gives a dropout rate of 7% of participants who suffered adverse events of morphine of sufficient intensity that they could not continue treatment. While every effort has been made to identify all participants in each study, these estimates will be affected by any failures to report this information in the included studies. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003868-sec-0085" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003868-sec-0085"></div> <p>This is the third update of the original Cochrane review first published in 2003. We identified no new studies for inclusion in this update, and the conclusions remain unchanged. </p> <section id="CD003868-sec-0086"> <h3 class="title" id="CD003868-sec-0086">Summary of main results</h3> <p>This review has 62 included studies with 4241 participants. The main results of this review are that oral morphine works well in cancer pain, providing over 90% of participants with no worse than mild pain where this was reported. Over 60% of participants using oral morphine registered outcomes like measures of satisfaction. Oral morphine for routine use at the correct dose for an individual is as effective as other opioids. </p> <p>This review might not change practice but it provides support for current practice. In particular, new studies included in the previous update confirmed that there is no significant difference in pain relief whether 24‐hour morphine modified release (Mm/r) preparations are administered in the morning or evening (<a href="./references#CD003868-bbs2-0009" title="CurrowDC , PlummerJL , CooneyNJ , GormanD , GlarePA . A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer. Journal of Pain and Symptom Management2007;34:17-23. ">Currow 2007</a>), nor whether 12‐hourly or 24‐hourly Mm/r preparations are used (<a href="./references#CD003868-bbs2-0046" title="RidgwayD , SopataM , BurneckisA , JespersenL , AndersenC . Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study. Journal of Pain and Symptom Management2010;39:712-20. ">Ridgway 2010</a>). The often‐asked clinical question of whether or not a double dose at bedtime improves pain relief remains unanswered. In two new studies included in this review, there was no significant difference in achievement of no worse than mild pain, participant preference (<a href="./references#CD003868-bbs2-0010" title="DaleO , PiribauerM , KaasaS , MoksnesK , KnobelH , KlepstadP . A double-blind, randomized, crossover comparison between single-dose and double-dose immediate-release oral morphine at bedtime in cancer patients. Journal of Pain and Symptom Management2009;37:68-76. ">Dale 2009</a>), or use of breakthrough analgesia (<a href="./references#CD003868-bbs2-0050" title="ToddJ , ReesE , GwilliamB , DaviesA . An assessment of the efficacy and tolerability of a 'double dose' of normal-release morphine sulphate at bedtime. Palliative Medicine2002;16:507-12. ">Todd 2002</a>), whether the participant had a single or double dose of morphine immediate release (MIR) at bedtime. However, both studies are probably too small to justify a change in practice in either direction. The 2007 update of this review indicated that titrating to analgesic effect with Mm/r was as effective as with MIR, and that there was no difference in achieving no worse than mild pain when Mm/r tablets are compared to Mm/r administered rectally or Mm/r oral suspension. Pain relief was also equally effective with oral morphine or epidural morphine: the latter caused fewer side effects but was associated with more technical problems. Based on the findings of this review, patient preference and other practical factors should continue to guide local practice. </p> <p>There is also no conclusive evidence that other strong opioids are superior in efficacy to morphine. The new studies included in this review showed that there was no difference in pain intensity whether participants received Mm/r or fentanyl or methadone (<a href="./references#CD003868-bbs2-0036" title="MercadanteS , PorzioG , FerreraP , FulfaroF , AielliF , VernaL , et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. European Journal of Pain2008;12:1040-6. ">Mercadante 2008</a>), or oxycodone (<a href="./references#CD003868-bbs2-0037" title="MercadanteS , TirelliW , DavidF , ArcaraC , FulfaroF , CasuccioA , et al. Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study. Clinical Journal of Pain2010;26(9):294-7. ">Mercadante 2010</a>). The Cochrane review by <a href="./references#CD003868-bbs2-0174" title="QuigleyC . Hydromorphone for acute and chronic pain. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD003447. [DOI: 10.1002/14651858.CD003447]">Quigley 2007</a> concluded that there was little difference between hydromorphone and morphine in terms of analgesic efficacy, adverse effect profile, and patient preference, but one of the new studies included in this review showed a small but statistically significant difference in benefit of hydromorphone over Mm/r (<a href="./references#CD003868-bbs2-0022" title="HannaM , ThipphawongJ . A randomized, double-blind comparison of OROS hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. ">Hanna 2008</a>). Fentanyl and oxycodone are both subjects of other Cochrane reviews (<a href="./references#CD003868-bbs2-0155" title="HadleyG , DerryS , MooreRA , WiffenPJ . Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 10. Art. No: CD010270. [DOI: 10.1002/14651858.CD010270.pub2]">Hadley 2013</a>; <a href="./references#CD003868-bbs2-0177" title="Schmidt-HansenM , BennettMI , ArnoldS , BromhamN , HilgartJS . Oxycodone for cancer-related pain. Cochrane Database of Systematic Reviews2015, Issue 2. Art. No: CD003870. [DOI: 10.1002/14651858.CD003870.pub5]">Schmidt‐Hansen 2015</a>). </p> </section> <section id="CD003868-sec-0087"> <h3 class="title" id="CD003868-sec-0087">Overall completeness and applicability of evidence</h3> <p>Most of the studies compared different formulations of oral morphine, or oral morphine with other oral opioids, or occasionally oral morphine with opioids using different routes of administration. There was no corpus of evidence for any particular comparison. The evidence would still have been useful if one of the outcomes reported consistently was that of participants obtaining good levels of pain relief, ideally no worse than mild pain, a patient‐reported outcome of acknowledged benefit (<a href="./references#CD003868-bbs2-0169" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400-12. [DOI: 10.1111/anae.12148]">Moore 2013a</a>). Only nine of the 62 included studies reported this, although seven reported other outcomes of value from the patient perspective. </p> <p>Most reported pain intensity as a mean, often with considerable variability around the mean. It was frequently the case that mean pain intensity scores were low and below (say) 30/100 mm. While average values are of questionable value in pain studies (<a href="./references#CD003868-bbs2-0164" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews. Pain2010;14(7):386-9. [DOI: 10.1016/j.pain.2010.05.011]'>Moore 2010a</a>; <a href="./references#CD003868-bbs2-0167" title="MooreRA , MhuircheartaighRJ , DerryS , McQuayHJ . Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology2011;28(6):427-32. [DOI: 10.1097/EJA.0b013e328343c569]">Moore 2011</a>), average values did support the results in individuals. It was frustrating that reporting was not more appropriate and applicable to individual patients. </p> <p>Applicability of the evidence was also hindered by a general concentration on studies attempting to discern small differences in effect or harm between formulations or opioids, or both. The concentration was on statistical rather than clinically useful outcomes. </p> </section> <section id="CD003868-sec-0088"> <h3 class="title" id="CD003868-sec-0088">Quality of the evidence</h3> <p>The quality of the evidence was limited by an absence of double‐blinding in a significant minority of studies, and small size in a substantial majority. Only 11 of the 62 studies included at least 100 participants and many had fewer than 50 participants (37/62). </p> </section> <section id="CD003868-sec-0089"> <h3 class="title" id="CD003868-sec-0089">Potential biases in the review process</h3> <p>We are unaware of any potential biases in the review process.</p> </section> <section id="CD003868-sec-0090"> <h3 class="title" id="CD003868-sec-0090">Agreements and disagreements with other studies or reviews</h3> <p>The results of this review are broadly in agreement with previous versions. A systematic review for the European Palliative Care Research Collaborative guidelines project included 17 studies, and concluded that their findings were identical to those of the Cochrane reviews on the topic (<a href="./references#CD003868-bbs2-0149" title="CaraceniA , PigniA , BrunelliC . Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. Palliative Medicine2011;25(5):402-9. [DOI: 10.1177/0269216310392102]">Caraceni 2011</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003868-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/urn:x-wiley:14651858:media:CD003868:CD003868-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003868-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_n/nCD003868-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_t/tCD003868-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/full#CD003868-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_n/nCD003868-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003868-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/urn:x-wiley:14651858:media:CD003868:CD003868-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003868-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_n/nCD003868-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_t/tCD003868-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/full#CD003868-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_n/nCD003868-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003868-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/urn:x-wiley:14651858:media:CD003868:CD003868-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003868-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_n/nCD003868-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_t/tCD003868-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/full#CD003868-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_n/nCD003868-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003868-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/urn:x-wiley:14651858:media:CD003868:CD003868-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Percentage of participants with oral morphine reporting no worse than mild pain. The size of the symbol is proportional to the size of the sample" data-id="CD003868-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_n/nCD003868-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_t/tCD003868-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Percentage of participants with oral morphine reporting no worse than mild pain. The size of the symbol is proportional to the size of the sample </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/full#CD003868-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_n/nCD003868-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003868-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/urn:x-wiley:14651858:media:CD003868:CD003868-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Percentage of participants with oral morphine reporting an outcome equivalent to treatment success. The size of the symbol is proportional to the size of the sample" data-id="CD003868-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_n/nCD003868-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_t/tCD003868-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Percentage of participants with oral morphine reporting an outcome equivalent to treatment success. The size of the symbol is proportional to the size of the sample </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/full#CD003868-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003868.pub4/media/CDSR/CD003868/image_n/nCD003868-FIG-05.png" target="_blank">Open in new tab</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003868.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003868-note-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003868-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003868-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD003868-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD003868-note-0011">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD003868-note-0009">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD003868-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD003868-note-0007">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD003868-note-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003868-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003868-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003868\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003868\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003868\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003868\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003868\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003868\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003868\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003868\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003868\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003868\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003868\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003868\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003868\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003868\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003868\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003868\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003868\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003868\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003868.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003868.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003868.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003868.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003868.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714607091"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003868.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714607094"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003868.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d72cdb8c7937f',t:'MTc0MDcxNDYwNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 